Document:

EX-10.23

 Exhibit 10.23 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 AMENDED AND
RESTATED 
 MANUFACTURING SERVICES AGREEMENT 

This Amended and Restated Manufacturing Services Agreement (the “Agreement”) is made as of August 26,
2013 (the “Restatement Date”), between Lonza Houston, Inc., a Delaware corporation having its principal place of business at 8066 El Rio St., Houston, TX 77054 (“LHI”), and Celladon
Corporation, a Delaware corporation, having an office at 12760 High Bluff Drive, Suite 240, San Diego, CA 92130 (“CLIENT”) (each of LHI and CLIENT, a “Party” and, collectively, the
“Parties”). 
 RECITALS 

A.        LHI and CLIENT are parties to that certain Manufacturing Services Agreement
dated August 24, 2012 (the “Original MSA”), and now wish to amend and restate the Original MSA in its entirety as set forth herein, effective as of the Restatement Date. 

B.        LHI operates a multi-client production facility located at 8066 El Rio St.,
Houston, TX 77054 (the “Facility”). 
 C.        CLIENT desires to
have LHI conduct work according to one or more individual Statements of Work, as further defined in Section 1.33 below. 

D.        CLIENT desires to have LHI perform manufacturing processes to produce one or
more products, one of which containing a recombinant viral vector and intended for therapeutic use in humans, and LHI desires to produce such product. 

E.        CLIENT desires to have LHI manufacture its proprietary AAV1-SERCA2a drug
substance, an adenovirus-associated virus based vector containing the expression cassette for SERCA2a, and LHI desires to manufacture such product. 

NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants hereinafter set forth, LHI and CLIENT,
intending to be legally bound, hereby agree as follows: 
 AGREEMENT 

1.        DEFINITIONS 

When used in this Agreement, capitalized terms will have the meanings as defined below and throughout the Agreement. Unless the
context indicates otherwise, the singular will include the plural and the plural will include the singular. 

1.1        “Acceptance Period”    shall have the
meaning set forth in Section 5.2.2. 

1.2        “Affiliate”    means, with respect to
either Party, any other corporation or business entity that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, the term
“control” 

  
 1. 

 
and, with correlative meanings, the terms “controlled by” and “under common control with” means direct or indirect ownership of more than fifty percent (50%) of the
securities or other ownership interests representing the equity voting stock or general partnership or membership interest of such entity or the power to direct or cause the direction of the management or policies of such entity, whether through the
ownership of voting securities, by contract, or otherwise. 

1.3        “Batch”    means a specific quantity
of Product that is intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture 

1.4        “Batch Record”    means the production
record pertaining to a Batch. 

1.5        “cGMP”    means the regulatory
requirements for current good manufacturing practices promulgated by the FDA under 21 CFR Parts 210 and 211, and by the provisions of EC Commission Directive 2003/94/EC together with the Guide to Good Manufacturing Practice published by the EC
Commission in 1992 (ISBN 92-826-3180-X), in each case as amended from time to time, and as interpreted by ICH Harmonised Tripartite Guideline, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. 

1.6        “Change Order”    has the meaning set
forth in Section 2.2. 
 1.7        “CLIENT Background
IP”    means Intellectual Property, media, assays methods, cell lines, or virus constructs either (i) owned, licensed or otherwise Controlled by CLIENT as of the Effective Date or (ii) developed or acquired by
CLIENT independently from performance under this Agreement during the term of this Agreement. 

1.8        “CLIENT Development Materials”    has
the meaning set forth in Section 2.3. 
 1.9        “CLIENT
Materials”    means the CLIENT Development Materials and the CLIENT Production Materials. 

1.10        “CLIENT Personnel”    has the meaning
set forth in Section 4.6.1. 
 1.11        “CLIENT Production
Materials”    has the meaning set forth in Section 4.1. 

1.12        “Commencement Date”    means the date
set forth in the Statement of Work for the commencement of the production of the Product. 

1.13        “Confidential Information”    has the
meaning set forth in Section 9.1. 
 1.14        “Control” or
“Controlled”,    in the context of intellectual property rights of a Party, shall mean that such Party or its Affiliate owns or possesses rights to intellectual property sufficient to grant the applicable
license, sublicense or access (as appropriate) under this Agreement, without violating the terms of any agreement with a Third Party. 

1.15        “Disapproval Notice”    shall have
the meaning set forth in Section 5.2.2. 
 1.16        “Effective
Date”    means August 24, 2012. 

  
 2. 

1.17        “EMA”    means the European Medicines
Agency, and any successor agency thereof. 

1.18        “FDA”    means the U.S. Food and Drug
Administration, and any successor agency thereof. 

1.19        “Intellectual Property”    means any
and all inventions, whether or not patentable, worldwide patents, copyrights, trade secrets, know-how and all other intellectual property rights, including all applications and registrations with respect thereto, but excluding all trademarks, trade
names, service marks, logos and other corporate identifiers. 

1.20        “LHI Background IP”    means
Intellectual Property, media, assays, methods, cell lines, or virus constructs either (i) owned, licensed or otherwise Controlled by LHI as of the Effective Date or (ii) developed or acquired by LHI independently from performance under
this Agreement during the term of this Agreement. 
 1.21        “LHI
Operating Documents”    means LHI’s standard operating procedures, standard manufacturing procedures, protocols, validation documentation (excluding process validation documents solely related to CLIENT’s
Process or Product), and supporting documentation used by LHI, such as environmental monitoring, for operation and maintenance of the Facility and LHI equipment used in the process of producing the Product, excluding any of the foregoing that are
unique to the manufacture of Product or developed by LHI in the manufacture of and solely related to the Product. For clarity, CLIENT Materials shall not be included as LHI Operating Documents. 

1.22        “LHI Parties”    has the meaning set
forth in Section 14.2. 
 1.23        “LHI Technology
Transfer”    means the transfer of documentation, specifications (including raw material specifications), process validation documents specifically related to CLIENT’s Process or Product (but, for clarity, shall not
include LHI Operating Documents), and production process by LHI to CLIENT pertaining to each Process performed and/or developed by LHI hereunder. 

1.24        “Materials”    means all raw
materials and supplies to be used in the production of a Product. 

1.25        “Process”    means the manufacturing
process for a Product performed by LHI pursuant to the terms of this Agreement. 

1.26        “Product”    has the meaning set
forth in a Statement of Work. 
 1.27        “Product
Warranties”    means those warranties as specifically stated in Section 5.2.2. 

1.28        “Production Term”    shall have the
meaning set forth in Section 4.3. 
 1.29        “Regulatory
Approval”    means the approval by the FDA or EMA to market and sell the Product in the United States or the European Union, respectively. 

  
 3. 

1.30        “SOP”    means a standard operating
procedure. 
 1.31        “SOW
Documentation”    means the compilation of documentation generated by LHI in preparation of and during the performance of a given SOW, including, without limitation, executed batch records, component records, test
records and test record forms, certificates of analysis, study protocols, study summary reports, deviation reports, laboratory investigations, environment excursions, formulation records, and other related documents. 

1.32        “Specifications”    means the
applicable Product specifications set forth in the applicable Statement of Work or as modified from time to time upon mutual agreement of the Parties in connection with the production of a particular Batch of Product hereunder. 

1.33        “Statement of Work” or
“SOW”    means a written outline of a plan setting forth each Party’s responsibility with respect to the performance of a Process or manufacture of the Product or related activities that is executed by both
Parties pursuant to Section 2.1. 
 1.34        “Third
Party”    means any party other than LHI, CLIENT or their respective Affiliates. 

2.        STATEMENTS OF WORK - PROCESS
AND PRODUCT DEVELOPMENT; PERFORMANCE 

2.1        Statement of Work.    Prior to performing any
Process or Product development, technology transfer from CLIENT to LHI, Process, or Product manufacture, the Parties will collaborate to develop a Statement of Work, describing the activities to be performed by the Parties, or to be subcontracted by
LHI to Third Parties. It is contemplated that each separate project shall have its own Statement of Work. Each Statement of Work shall state that it is entered into pursuant to this Agreement and is subject in all respects to the terms and
conditions hereof. Once agreed to by the Parties, the Statement of Work shall be executed by each of the Parties. In the event of a conflict between the terms and conditions of this Agreement and any Statement of Work, the terms and conditions of
this Agreement shall control. 
 2.2        Modification of Statement of
Work.    Should CLIENT want to change a Statement of Work or to include additional services to be provided by LHI, CLIENT may propose to LHI an amendment to the applicable Statement of Work with the desired changes or
additional services (“Change Order”). If LHI reasonably determines that it has the resources and capabilities to accommodate such Change Order, LHI and CLIENT will negotiate in good faith a modified version of the Statement of Work
reflecting such Change Order (including, without limitation, any changes to the estimated timing, estimated charges or scope of a project). The modified Statement of Work shall be binding on the Parties only if it states that it is entered into
pursuant to this Agreement and is subject in all respects to the terms and conditions hereof, and is signed by both Parties. Whereafter such modified version of the Statement of Work will be deemed to have replaced the prior version of the Statement
of Work. Notwithstanding the foregoing, and following good faith negotiations of the Parties, if a modified version of the Statement of Work is not agreed to by both Parties, the existing Statement of Work shall remain in effect unless terminated by
CLIENT in its sole discretion upon thirty (30) days prior written notice, in which case CLIENT shall be responsible for any charges for materials that have already been purchased for such Statement of Work and CLIENT shall pay reasonable costs

  
 4. 

 
incurred by LHI up to the effective date of termination, including all un-cancellable labor commitments and all work in process including all professional services rendered through the effective
date of termination. 
 2.3        CLIENT
Deliverables.    Within the time period specified in the applicable Statement of Work, CLIENT will provide LHI with (a) the materials listed in the Statement of Work for which CLIENT is responsible for delivering to LHI,
and any handling instructions, protocols, SOPs and other documentation necessary to maintain the properties of such materials for the performance of the Statement of Work, and (b) any protocols, SOPs and other information and documentation in
possession or control of CLIENT and necessary for the performance of the Statement of Work, and for the preparation of the SOW Documentation in conformance with cGMP, including, without limitation, process information, SOPs, development data and
reports, quality control assays, raw material specifications (including vendor, grade and sampling/testing requirements), product and sample packing and shipping instructions, and product specific cleaning and decontamination information,
(collectively, the “CLIENT Development Materials”). If CLIENT does not provide the CLIENT Development Materials within the time period specified in a Statement of Work, then CLIENT shall be responsible for any costs incurred by LHI
arising from such failure. 
 2.4        Performance by
LHI.    Subject to the provision by CLIENT of the CLIENT Development Materials pursuant to Section 2.3, LHI will use commercially reasonable efforts to perform, directly or through a Third Party contractor (provided such
Third Party contractor is specified in the Statement of Work or approved by CLIENT in writing, such approval not to be unreasonably withheld), the work described in each applicable Statement of Work, LHI will perform such work in a professional and
workmanlike manner in accordance with the terms of this Agreement and all applicable federal, state, and local laws, rules and regulations in the United States or European Union. LHI will use commercially reasonable efforts to promptly notify CLIENT
of any material delays that arise during the performance of the Statement of Work. 
 3.    VALIDATION;
TECHNOLOGY TRANSFER 
 3.1        As set
forth in the applicable Statement of Work, LHI will prepare the SOW Documentation for the applicable Process in accordance with the schedule set forth in the applicable Statement of Work, Specifications, the LHI Operating Documents and written
information provided by CLIENT. CLIENT will inform LHI of any specific requirements CLIENT may have relating to the SOW Documentation, including, without limitation, any information or procedures CLIENT wishes to have incorporated therein. If LHI
intends to include in the SOW Documentation the use of any assay, medium, or other technology that is not commercially available, LHI will inform CLIENT of such intention and the Parties will meet to discuss and attempt to agree in good faith on the
terms of use of such non-commercially available materials or technology in the Process. The SOW Documentation shall be completed and delivered by LHI at completion of a Batch. 

3.2        CLIENT will cooperate with LHI to assist LHI to develop the SOW
Documentation and a Process in accordance with the applicable Statement of Work, including, without limitation, by providing LHI with additional information and procedures as may be 

  
 5. 

 
required to create the SOW Documentation, Process, and/or any of the following: (i) manufacturing process information, SOPs, development reports, (ii) quality control assays,
(iii) raw material specifications (including vendor, grade and sampling/testing requirements), (iv) Product and sample packing and shipping instructions, (v) Product specific cleaning and decontamination information. 

3.3        LHI will deliver a draft version of each SOW Documentation to CLIENT
for its review and approval in accordance with the schedule set forth in the applicable Statement of Work. CLIENT will notify LHI in writing of any objections it has to such draft SOW Documentation, and upon such notification, representatives of LHI
and CLIENT will meet promptly to resolve such objections. Upon CLIENT’s written acceptance of the draft SOW Documentation, or in the event that CLIENT does not submit a written notice setting forth CLIENT’s objections to the draft SOW
Documentation within twenty (20) days following receipt of such draft by CLIENT, such draft will be deemed approved by CLIENT. 

3.4        LHI Technology Transfer.    Subject to the terms
set forth herein, upon CLIENT’s reasonable request and at CLIENT’s reasonable cost, LHI will provide technology transfer assistance services to CLIENT in order to establish of Product manufacturing capabilities at CLIENT’s facility or
at one or more Third Party contract manufacturers selected by CLIENT solely for the purposes of manufacturing the Product; provided, however, to the extent such technology transfer includes any LHI Materials, LHI Background IP or LHI
Confidential Information, the Parties shall negotiate in good faith a reasonable royalty and/or licensing fee to be paid to LHI for the use of or reference to LHI Materials, LHI Background IP or LHI Confidential Information. Such technology transfer
assistance shall be limited to LHI Technology Transfer to CLIENT or its Third Party contract manufacturer, which LHI Technology Transfer shall not include training; provided, however, if LHI terminates this Agreement in accordance with
Section 13.3.2 or CLIENT terminates this Agreement in accordance with Section 13.2, then as reasonably requested by CLIENT, during the [...***...] month period following any such termination, LHI shall make available employees of it and
its Affiliates to CLIENT, at CLIENT’s cost and expense, to provide reasonable technical support and assistance, for a duration of time not to exceed [...***...] months and at mutually agreed locations to facilitate an orderly transition of LHI
Technology Transfer and operations. Notwithstanding the foregoing, LHI must, in writing, provide prior notice to CLIENT of its use or its intention to use any LHI Materials, LHI Background IP or LHI Confidential Information in performance of the
services of this Agreement. CLIENT must agree, in writing, to LHI’s use of any LHI Materials, LHI Background IP or LHI Confidential Information in performance of the services of this Agreement. Absent such notification by LHI and acceptance by
the CLIENT, if LHI includes any LHI Materials, LHI Background IP or LHI Confidential Information in the performance of the services of this Agreement, LHI hereby grants to CLIENT a non-exclusive, irrevocable, fully paid-up, royalty-free,
transferable, worldwide license, with the right to sub-license, to use the LHI Materials, LHI Background IP or LHI Confidential Information, solely to the extent necessary for making, using, selling, or offering for sale any Product manufactured
hereunder. From time to time as reasonably requested by CLIENT during the term of the Agreement, and in any case upon any material change in or update to any of the Specifications for Product, LHI will provide CLIENT, or its designated contract
manufacturer, with copies of the LHI Technology Transfer documentation, to the extent not already provided, including 
  

***Confidential Treatment Requested 

  
 6. 

 
without limitation: (a) all technical reports and materials for process development activities completed at the time of such transfer that are relevant to and would be required to
manufacture Product using the processes as performed by LHI at such time (including but not limited to any recovery steps established, process validation, product identity assays, in-process-control assays, applicable computer software, relevant
standard operating procedures (provided, however, LHI shall not be obligated to provide any LHI Operating Documents), (b) all regulatory filings relating to the manufacturing process or Product, and (c) all necessary CMC documentation
relating to the manufacturing process for Product and required for regulatory filings or compliance. 

4.        MANUFACTURE OF PRODUCT; ORDER
PROCESS; DELIVERIES 
 4.1        CLIENT
Deliverables.    Within the time period agreed to in the applicable Statement of Work, CLIENT will provide LHI with the materials listed in such Statement of Work required to be supplied by CLIENT for the manufacture of a
Product, and any handling instructions, protocols, SOPs and other documentation necessary to maintain the properties of such materials for the performance of the applicable Statement of Work (collectively, the “CLIENT Production
Materials”). 
 4.2        Commencement
Date.    Each Statement of Work governing the manufacture of Product will include a Commencement Date agreed upon by the Parties. LHI will commence manufacture of Product on or before the Commencement Date. 

4.3        Manufacture by LHI.    During the time
period specified in any Statement of Work during which Product will be manufactured (the “Production Term”), LHI will use commercially reasonable efforts to manufacture, package, ship, handle quality assurance and quality control
for the Product, all as set forth in the applicable Statement of Work, and to deliver to CLIENT the quantities of Product requested by CLIENT in such Statement of Work, all in accordance with the terms set forth in Section 4.4 below.
Notwithstanding the foregoing, LHI shall have the right to revise the production schedule with respect to a Statement of Work provided that such schedule does not advance or delay commencement of the production of Batches under a Statement of Work
by more than sixty (60) days. 
 4.4        Packaging and
Shipping.    LHI will package and label the Product for shipment in accordance with the SOW Documentation, the Specifications and LHI’s standard practices in effect at the time of performance by LHI. LHI will ship
Product FCA Facility using a common carrier designated by CLIENT to LHI in writing not less than ten days prior to the applicable delivery date unless otherwise agreed to in the applicable Statement of Work. CLIENT will provide to LHI its account
number with the selected carrier and will pay for all shipping costs in connection with each shipment of Product. Each shipment will be accompanied by the documentation listed in the SOW Documentation or the applicable Statement of Work. Risk and
title in the Product will pass upon delivery to the carrier. LHI will use commercially reasonable efforts to deliver each shipment of Product to CLIENT on the requested delivery date for such shipment. LHI will promptly notify CLIENT if LHI
reasonably believes that it will be unable to meet the requested delivery date specific in the applicable purchase order for such shipment; the giving of such notice will not otherwise excuse LHI’s performance under this Agreement. CLIENT shall
be required to take delivery of a Batch of Product within thirty (30) days after acceptance of such Batch in accordance with Section 5.2 (the “Delivery Period”), unless

  
 7. 

 
CLIENT requests in writing, and LHI consents in writing, to store the material on CLIENT’s behalf and at CLIENT’s expense. 

4.5        Records. LHI will maintain complete and accurate records for the
manufacture of each Batch of Product and the development of any Process, if applicable, as required by applicable laws and regulations. LHI will retain possession of the SOW Documentation, all Batch Records and LHI Operating Documents, and will
promptly provide copies thereof upon CLIENT’s request and at CLIENT’s expense; provided however, LHI shall provide electronic copies of such documents, at CLIENT’s request, at no cost to CLIENT. LHI Operating Documents will remain LHI
Confidential Information. CLIENT has the right to use and reference any of the foregoing in connection with a filing for Regulatory Approval of the Product, to authorize release and final acceptance of Product delivered hereunder or as otherwise
authorized by the Agreement. 
 4.6        CLIENT Access. 

4.6.1        CLIENT’s employees and agents (including its independent
contractors) (collectively, “CLIENT Personnel”) may participate in the production of the Product only in such capacities as may be approved in writing in advance by LHI; provided, however, upon reasonable advance notice to
LHI, CLIENT Personnel shall have the right to be present at the Facility to observe the production of Product for a reasonable amount of time. CLIENT Personnel working at the Facility are required to comply with LHI’s Operating Documents and
any other applicable LHI facility and/or safety policies. For the avoidance of doubt, CLIENT Personnel may not physically participate in the production or manufacture of any Product that may be used in or on humans. 

4.6.2        CLIENT Personnel working at the Facility will be and remain
employees of CLIENT, and CLIENT will be solely responsible for the payment of compensation for such CLIENT Personnel (including applicable Federal, state and local withholding, FICA and other payroll taxes, workers’ compensation insurance,
health insurance, and other similar statutory and fringe benefits). CLIENT covenants and agrees to maintain workers’ compensation benefits and employers’ liability insurance as required by applicable Federal and state laws with respect to
all CLIENT Personnel working at the Facility. 
 4.6.3        CLIENT will pay
for the actual cost of repairing or replacing to its previous status (to the extent that LHI determines, in its reasonable judgment, that repairs cannot be adequately effected) any property of LHI damaged or destroyed by CLIENT Personnel, provided
CLIENT shall not be liable for repair or replacement costs resulting from ordinary wear and tear. 

4.6.4        CLIENT Personnel visiting or having access to the Facility will
abide by LHI standard policies, operating procedures and the security procedures established by LHI and brought to the attention of such CLIENT Personnel prior to any visits or access to the Facility. CLIENT will be liable for any breaches of
security by CLIENT Personnel. In addition, CLIENT will reimburse LHI for the cost of any lost security cards issued to CLIENT Personnel, at the rate of $50 per security card. All CLIENT Personnel will agree to abide by LHI policies and SOPs
established by LHI, and will sign an appropriate confidentiality agreement if one is not already in place with CLIENT governing such obligations. 

  
 8. 

 4.6.5        CLIENT will indemnify
and hold harmless LHI from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) arising out of any injuries suffered by CLIENT Personnel while at the Facility or elsewhere,
except to the extent caused by the gross negligence or willful misconduct on the part of any LHI Party, or resulting from a breach of this Agreement by an LHI Party. 

4.7        Disclaimers.    Each Party acknowledges and
agrees that LHI Parties will not engage in any Product refinement or development of the Product, other than as expressly set forth in this Agreement and each applicable Statement of Work. Each Party acknowledges and agrees that LHI Parties have not
participated in the invention or testing of any Product, and have not evaluated its safety or suitability for use in humans or otherwise. 

4.8        Quality Agreement.    Prior to the Restatement
Date, the Parties entered into a separate quality agreement which describes the responsibilities of each Party’s quality unit related to the manufacture of Product (the “Quality Agreement”). In the event of any conflict or
inconsistency between the Quality Agreement and this Agreement, this Agreement shall govern at all times. 

4.9        Genetic Alterations.    LHI is not responsible
for any genetic alterations that occur during production of any product, except for those genetic alterations that result from a grossly negligent or intentionally wrongful act or omission of LHI and not as a result of the predisposition of any
material provided by CLIENT. Unless they arise from a grossly negligent or intentionally wrongful act or omission of LHI, genetic alterations shall not be the basis for a breach of warranty claim by CLIENT. If LHI fails to deliver materials in
accordance with the terms of this Agreement or a Statement of Work, or if materials produced pursuant to the Statement of Work fail to meet any technical specification required by the Statement of Work, and such failure is due to genetic alterations
which do not arise from a grossly negligent or intentionally wrongful act or omission of LHI, at CLIENT’s option, LHI will re-perform the specific project at issue at the earliest practicable time, for an additional fee equal to the original
fee for that part of the project. 
 5.        PRODUCT WARRANTIES;
ACCEPTANCE AND REJECTION OF PRODUCTS 

5.1        Product Warranties.    LHI represents and
warrants that all Product manufactured by LHI pursuant to this Agreement, at the time of delivery pursuant to Section 4.4: (a) shall conform to the Specifications; (b) was manufactured in accordance with the SOW Documentation; and
(c) where applicable, was manufactured in accordance with cGMP and any other applicable United States or European Union regulatory standards. LHI further represents and warrants that all Product manufactured hereunder is free and clear of any
encumbrances, liens or other Third Party claims, including any claims of an approved subcontractor. 

5.2        Approval of Completed Product. 

5.2.1        When a SOW has been completed, LHI will notify CLIENT and supply
CLIENT with the required documentation set forth in the SOW. 

5.2.2        Within fifteen (15) calendar days after CLIENT’s receipt
of such documentation regarding such Product or within such time as mutually agreed by the Parties in 

  
 9. 

 
writing (the “Acceptance Period”), Client shall determine by review of such documentation whether or not the given Batch conforms to the product warranties set forth in
Section 5.1 above (“Product Warranties”). If CLIENT asserts that any quantity of Product does not comply with the Product Warranties set forth in Section 5.1 above (a “Defective Product”), CLIENT will
deliver to LHI, in accordance with the notice provisions set forth in Section 16.4 hereof, written notice of disapproval (the “Disapproval Notice”) of such Product, stating in reasonable detail the basis for such assertion of
non-compliance with the Product Warranties. If a valid Disapproval Notice is received by LHI during the Acceptance Period, then LHI and CLIENT will provide one another with all related paperwork and records (including, but not limited to, quality
control tests) relating to the manufacture of Product and the Disapproval Notice. If a valid Disapproval Notice is agreed upon or if any dispute regarding the conformity of a Batch of Product with the Product Warranties is resolved in favor of
CLIENT in accordance with the terms set forth in Section 5.3 below, CLIENT, in its sole discretion, may return any quantity of Defective Product or the entire Batch of Product from which Defective Product is derived. If a valid Disapproval
Notice is not received during the Acceptance Period, Product will be deemed accepted and ready for shipment to CLIENT, or storage for CLIENT, as applicable, in each case, subject to the detection of any Latent Defects as described in
Section 5.3. If Product is to be shipped to CLIENT, then upon acceptance, the Product shall be delivered to CLIENT and CLIENT shall accept delivery thereof in accordance with Section 4.4. Title and risk of loss to such Product shall pass
to CLIENT at the time of delivery to the common carrier pursuant to Section 4.4. If the Product is to be stored by LHI for CLIENT, LHI shall do so in accordance with agreed upon terms of a SOW which covers all relevant details of a Product
storage engagement. 
 5.3        Latent Defects.    If,
within [...***...] months after CLIENT’s initial acceptance or deemed acceptance (as described in Section 5.2.2) of a delivery of a Batch of Product, CLIENT determines that any
such quantity of Product delivered hereunder is Defective Product, CLIENT will, promptly after such determination, inform LHI in writing about such Defective Product. LHI will reasonably cooperate with any subsequent investigation CLIENT may conduct
and will engage in good faith discussions with CLIENT to determine the cause of such defect(s). If the Parties determine that the defect could not have been reasonably determined by CLIENT’s release testing and the defect existed at the time of
CLIENT’s initial acceptance or deemed acceptance (as described in Section 5.2.2) (a “Latent Defect”), then CLIENT may revoke its acceptance with respect to such quantity of Product containing a Latent Defect by providing
written notice to LHI of such revocation and the terms of Section 5.5 shall apply. If CLIENT does not notify LHI of a Latent Defect within [...***...] months after CLIENT’s initial acceptance or deemed acceptance (as described in
Section 5.2.2), CLIENT waives all remedies at law or in equity regarding such claim that the Product is Defective Product. Product containing a Latent Defect shall be deemed Defective Product hereunder. CLIENT acknowledges and agrees that
[...***...] with respect to any Latent Defect [...***...]. 
  
 ***Confidential Treatment Requested 

  
 10. 

 5.4        Dispute
Resolution. LHI and CLIENT will attempt to resolve any dispute regarding the conformity of a Batch of Product with the Product Warranties. If such dispute cannot be settled within 30 days of the submission by each Party of the
related paperwork and records to the other Party, and if the Product is alleged not to conform with the Product Warranties set forth in Section 5.1(a), then CLIENT will submit a sample of the Batch of the disputed Product to an independent
testing laboratory of recognized repute or an independent consultant with relevant expertise related to the dispute, in each case selected by CLIENT and approved by LHI (such approval not to be unreasonably withheld) for analysis, under quality
assurance approved procedures, of the conformity of such Batch of Product with the Specifications. The costs associated with such analysis by such independent testing laboratory will be paid by the Party against whom the independent testing
laboratory decides. The determination by the independent testing laboratory shall be binding on the Parties. 

5.5        Remedies for Defective, Damaged, or Destroyed Product. 

5.5.1        In the event that: (i) the Parties agree, or an independent
testing laboratory or consultant determines, pursuant to Section 5.4, that a Batch of Product or portion thereof constitutes Defective Product (including Product containing a Latent Defect as described in Section 5.3), or (ii) Product
and/or Materials are destroyed or damaged by LHI Personnel, due to the failure of (a) LHI personnel to properly execute the SOW Documentation, (b) LHI personnel to comply with cGMP, or (c) the Facility or equipment utilities; then, in
each case, at CLIENT’s request, LHI will, as soon as it is commercially practicable to do so and not later than [...***...] months after CLIENT’s written request, produce for
CLIENT sufficient quantities of Product to replace such Defective Product or damaged or destroyed Product, as applicable (the “Production Rerun”), in accordance with the provisions of this Agreement. If CLIENT requests a Production
Rerun, then: (A) if CLIENT previously paid for such Defective Product or damaged or destroyed Product, the Production Rerun will be performed and the replacement Product will be provided at no additional cost to CLIENT; and (B) if CLIENT
did not pay for such Defective Product or damaged or destroyed Product, CLIENT shall be responsible for the price of the conforming Batch of Product provided to CLIENT from the Production Rerun. If CLIENT previously paid for such Defective Product
or damaged or destroyed Product, and CLIENT does not request a Production Rerun, then LHI will, at CLIENT’s option, either credit or refund any amounts paid by CLIENT for such Defective Product or damaged or destroyed Product. [...***...]. 

5.5.2        In the event that the Parties agree, or an independent testing
laboratory determines, pursuant to Section 5.4, that a Batch of Product or portion thereof constitutes Defective Product, or Product and/or Materials are destroyed or damaged by LHI Personnel, for any reason other than as set forth in
Section 5.5.1, then LHI shall have no liability to CLIENT with respect to such Batch, Product or Material and LHI will, at CLIENT’s request, produce for CLIENT a Production Rerun at CLIENT’s expense. Notwithstanding anything to the
contrary set forth in Section 5.5.1, if during the manufacture of Product pursuant to this Agreement, Product or Materials are destroyed or damaged by LHI Personnel while LHI Personnel were acting at the direction of CLIENT Personnel, then LHI
will have no liability to CLIENT as the result of such destruction or damage. 
  

***Confidential Treatment Requested 

  
 11. 

 5.5.3        Subject to this
Section 5.5.3, CLIENT acknowledges and agrees that [...***...] with respect to (i) the failure of Product to conform with any of the Product Warranties and (ii) damaged or destroyed Materials and/or Product, including without
limitation, Product containing Latent Defects, [...***...]. 
 6.        STORAGE OF
MATERIALS 

6.1        Pre-Production.    LHI will store at the
expense of CLIENT any CLIENT Materials, equipment or other property delivered pursuant to the applicable Statement of Work to the Facility by CLIENT for the performance of the applicable Process or the manufacture of Product. The storage rates will
be set forth in the applicable Statement of Work and may be amended from time to time by LHI with prior written notice to CLIENT. No storage fees will be charged during the period starting 30 days prior to the Commencement Date and ending upon
fifteen (15) days after the expiration or termination of the Production Term. 

6.2        Post-Production.    LHI will store at the
Facility free of charge any in–process materials, CLIENT Materials, equipment and other CLIENT property (other than Product manufactured hereunder) that remains at the Facility on the date of expiration or termination of the Production Term
(collectively “Remaining CLIENT Property”), for up to 15 calendar days. LHI shall provide CLIENT with a list of the Remaining CLIENT Property within 15 calendar days of the date of expiration or termination of the
Production Term. If CLIENT has not provided any instructions as to the shipment or other disposition of Remaining CLIENT Property prior to the expiration of such fifteen (15)-day period, LHI may, in its sole discretion, destroy such Remaining CLIENT
Property, or continue to store such Remaining CLIENT Property at the Facility or elsewhere. In the event that LHI continues to store such Remaining CLIENT Property, CLIENT will pay to LHI a storage charge at LHI’s then-standard monthly storage
rates for the period beginning on the sixteenth (16th) day after the expiration or termination of the Production Term through the date that the storage terminates. 

6.3        Product.    Notwithstanding the foregoing, if
CLIENT fails to take delivery of a Product within the applicable Delivery Period as required by Section 4.4, CLIENT will pay to LHI a storage charge at three times LHI’s then-standard monthly storage rate, which shall begin accruing on the
first day following the expiration of the applicable Delivery Period. 
 7.        REGULATORY
MATTERS 
 7.1        Permits and
Approvals.    During the Production Term, LHI will use commercially reasonable efforts to maintain any licenses, permits and approvals necessary for the manufacture of the Product in the Facility. LHI will promptly
notify CLIENT if LHI receives notice that any such license, permit, or approval is or may be revoked or suspended. 

7.2        Inspections/Quality Audit by
CLIENT.    Up to two times during each year of the term of this Agreement, and upon not less than 30 days’ prior written notice, CLIENT may inspect and audit the parts of the Facility where any activities
conducted hereunder with respect to the Process or the manufacture of the Product are carried out in order to assess LHI’s compliance with cGMP and other applicable practices or regulations, and to discuss any related 

 
 ***Confidential Treatment Requested 

  
 12. 

 
issues with LHI’s management personnel. In addition to such semi-annual audits, CLIENT may audit the Facility on a “for cause” basis as often as is required. CLIENT Personnel
engaged in such inspection will abide by the terms and conditions set forth in Sections 4.6.4 and 9. 

7.3        Inspections by Regulatory
Agencies.    LHI will promptly notify CLIENT if any regulatory agency visits the Facility concerning the manufacture of the Product. LHI will allow representatives of any regulatory agency to inspect the relevant parts
of the Facility where any activities conducted hereunder with respect to the manufacture of Product are carried out and to inspect the SOW Documentation and Batch Records to verify compliance with cGMP and other practices or regulations and will
promptly notify CLIENT of the scheduling of any such inspection. LHI will promptly send to CLIENT a copy of any reports, citations, or warning letters received by LHI in connection with an inspection of a regulatory agency to the extent such
documents relate to or affect the manufacture of the Product. CLIENT is permitted to be on site and available for questions regarding the Product during any such inspection. To the extent practicable, LHI shall furnish to CLIENT copies of proposed
responses to any regulatory agency with respect to any such inspection to the extent such proposed responses are related to the Product or Process, subject to redaction of LHI’s Confidential Information or other information of LHI that is
unrelated to the Product or its manufacture, as promptly as reasonably possible prior to the time it submits such responses. Prior to responding, to the extent practicable, LHI will discuss the proposed response with CLIENT and will implement in
good faith any comments provided by CLIENT relating to the Product which LHI deems applicable. After the filing of a response with any regulatory agency, LHI will notify CLIENT of any further written contacts with such regulatory agency relating to
the subject matter of the response. 
 8.        FINANCIAL TERMS 

8.1        Payments.    CLIENT will make payments to
LHI in the amounts and on the dates set forth in the Statement of Work upon receipt of an invoice from LHI. In the event that CLIENT has not paid an invoice within thirty (30) business days of the applicable due date (as established by
Section 8.2), CLIENT’s failure shall be considered a material breach under Section 13.2, subject to the cure provisions set forth therein. Further, in addition to all other remedies available to LHI, in the event that CLIENT has not
paid an undisputed invoice within sixty (60) business days of the applicable due date (as established by Section 8.2), LHI may elect to suspend the provision of all or a portion of the services under this Agreement, provided that CLIENT
shall remain liable for all fees owed pursuant to the Statement of Work during any such suspension. 

8.2        Invoices and Pricing.    LHI will charge for the
services in accordance with the price schedule in each individual Statement of Work. LHI will invoice CLIENT according to the schedule set forth in a Statement of Work. LHI will deliver invoices electronically by email, which shall be considered to
be an original invoice. Invoices should be e-mailed to [...***...]@celladon.net and/or to such other e-mail address(es) as CLIENT may stipulate from time to time. LHI will not deliver a
paper invoice. Payment of invoices is due as provided in the Statement of Work. All pricing excludes taxes and costs relating to shipping and regulatory filings. The price of Product manufactured outside of the United States shall be invoiced to

  

***Confidential Treatment Requested 

  
 13. 

 
CLIENT in either the local currency of the location of the facility in which the Product is manufactured or such other currency mutually agreed by the Parties. 

8.3        Taxes.    CLIENT agrees that it is
responsible for and will pay any sales, use or other taxes (the “Taxes”) resulting from LHI’s production of Product under this Agreement (except for income or personal property taxes payable by LHI). To the extent not paid by
CLIENT, CLIENT will indemnify and hold harmless the LHI Parties from and against any and all penalties, fees, expenses and costs whatsoever in connection with the failure by CLIENT to pay the Taxes. LHI will not collect any sales and use taxes from
CLIENT in connection with the production of any Product hereunder if CLIENT provides to LHI the appropriate valid exemption certificates. 

8.4        Interest.    Any fee, charge or other
payment due to LHI by CLIENT under this Agreement that is not paid within 30 days after it is due will accrue interest on a daily basis at a rate of 1.5% per month (or the maximum legal interest rate allowed by applicable law, if less)
from and after such date. 
 8.5        Method of
Payment.    Except as otherwise set forth in Section 8.2, all payments to LHI hereunder by CLIENT will be in United States currency and will be by check, wire transfer, money order, or other method of payment
approved by LHI. Bank information for wire transfers is as follows: 
 Mailing address for wire transfer payments: 

							
		 	 To:
	 	[...***...]	  	
		 	 Branch:
	 	[...***...]	  	
		 		 	[...***...]	  	
		 		 	[...***...]	  	
		 	 Wire ABA Routing:
	 	[...***...]	  	
		 	 Check-ACH ABA:
	 	[...***...]	  	
		 	 Account:
	 	[...***...]	  	
		 	 Remarks:
	 	[...***...]	  	

 8.6        Cost
Adjustments.    After the first anniversary of the Effective Date, LHI may annually adjust the various costs and rates set forth in the Statements of Work entered into by the Parties in the prior year to reflect changes in
the cost of materials and/or labor rate paid by LHI in connection with the manufacture of Product under this Agreement; provided, however, that any increase in labor rates shall not exceed any percentage increase in the US Consumer Price
Index for the most recently published percentage change for the 12-month period preceding the applicable contract anniversary date. LHI agrees to provide CLIENT with written notice of any such cost adjustment prior to such cost adjustment taking
effect. In addition to the foregoing, the price may be changed by LHI, upon reasonable prior written notice to CLIENT (providing reasonable detail in support thereof), to reflect any material change in an environmental or regulatory standard that
substantially impacts LHI’s cost and ability to manufacture Product. 
  

***Confidential Treatment Requested 

  
 14. 

 9.        CONFIDENTIAL INFORMATION

 9.1        Definition.    “Confidential
Information” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, specifications, data, results
and other material, pre-clinical and clinical trial results, manufacturing procedures, test procedures and purification and isolation techniques, and any tangible embodiments of any of the foregoing, and any scientific, manufacturing, marketing and
business plans, any financial and personnel matters relating to a Party or its present or future products, sales, suppliers, customers, employees, investors or business, that has been disclosed by or on behalf of such Party or such Party’s
Affiliates to the other Party or the other Party’s Affiliates either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing this Agreement. Without limiting the foregoing, (a) all
information that was disclosed by the Parties prior to the Effective Date pursuant to the Reciprocal Confidentiality Agreement entered into by the Parties dated November 30, 2010, as amended, will be considered “Confidential
Information” hereunder, (b) the terms of this Agreement will be deemed “Confidential Information” of both Parties and will be subject to the terms and conditions set forth in this Article 9, and (c) all Processes
provided by CLIENT hereunder, the Specifications and any Confidential Information solely related to Product will be deemed the “Confidential Information” of CLIENT and will be subject to the terms and conditions set forth in this
Article 9. 

9.2        Exclusions.    Notwithstanding the
foregoing Section 9.1, any information disclosed by a Party to the other Party will not be deemed “Confidential Information” of the disclosing Party to the extent that such information: 

(a)        at the time of disclosure is in the public domain; 

(b)        becomes part of the public domain, by publication or otherwise,
through no fault of the Party receiving such information; 
 (c)        at
the time of disclosure is already in possession of the Party who received such information, as established by contemporaneous written records; 

(d)        is lawfully provided to the receiving Party, without restriction as
to confidentiality or use, by a Third Party lawfully entitled to possession of such Confidential Information; or 

(e)        is independently developed by the receiving Party without use of or
reference to the disclosing Party’s Confidential Information, as established by contemporaneous written records. 

9.3        Disclosure and Use Restriction.    Except
as expressly provided herein, the Parties agree that for the term of the Agreement and the ten-year period following any termination or expiration of the Agreement, each Party and its Affiliates will keep completely confidential and will not publish
or otherwise disclose any Confidential Information of the other Party, its Affiliates or sublicensees, except in accordance with Section 9.4. Neither Party will use 

  
 15. 

 
Confidential Information of the other Party except as necessary to perform its obligations or to exercise its rights under this Agreement. 

9.4        Permitted Disclosures.    Each receiving
Party agrees to (i) institute and maintain security procedures to identify and account for all copies of Confidential Information of the disclosing Party and (ii) limit disclosure of the disclosing Party’s Confidential Information to
its U.S. and European Affiliates and each of its and their respective officers, directors, employees, agents, consultants and independent contractors having a need to know such Confidential Information for purposes of this Agreement; provided that
such U.S. and European Affiliates and each of its and their respective officers, directors, employees, agents, consultants and independent contractors are informed of the terms of this Agreement and are subject to obligations of confidentiality,
non-disclosure and non-use at least as restrictive as those set forth herein. 

9.5        Government-Required Disclosure.    If a
duly constituted government authority, court or regulatory agency orders that a Party hereto disclose information subject to an obligation of confidentiality under this Agreement, such Party shall comply with the order, notwithstanding the
obligations of confidentiality or limitations on use in this Agreement, and shall notify the other Party as soon as reasonably possible, so as to provide such other Party an opportunity to apply to a court of record for relief from the order. The
Party ordered to make such disclosure shall reasonably cooperate and assist such other Party to the extent necessary to obtain such relief from the order or obtain confidential treatment of the information disclosed. 

9.6        Publicity.    Neither Party will refer
to, display or use the other’s name, trademarks or trade names, including those confusingly similar thereto, alone or in conjunction with any other words or names, in any manner or connection whatsoever, including any publication, article, or
any form of advertising or publicity, except with the prior written consent of the other Party. Notwithstanding the foregoing, for general business development purposes, LHI may announce on its website or in press releases the general nature of work
performed for CLIENT under any given Statement of Work upon receiving permission from CLIENT, such permission not being unreasonably withheld or delayed. 

10.        INTELLECTUAL PROPERTY 

10.1        Ownership. 

10.1.1        Except as expressly otherwise provided herein, neither Party will,
as a result of this Agreement, acquire any right, title, or interest in any Intellectual Property of the other Party. Except as expressly otherwise provided herein, ownership of any Intellectual Property that is developed, conceived, invented, first
reduced to practice or made in connection with the performance under this Agreement shall follow inventorship all as determined under applicable laws. 

10.1.2        As between the Parties, CLIENT shall own all right, title, and
interest in and to any and all Intellectual Property that LHI and/or its Affiliates develops, conceives, invents, first reduces to practice or makes, solely or jointly with CLIENT or others in the course of or resulting from the performance of a
Statement of Work (collectively, “CLIENT New IP”). Notwithstanding the foregoing, in the event that CLIENT agrees in writing to LHI’s use of any 

  
 16. 

 
LHI Materials, LHI Background IP or LHI Confidential Information in accordance with Section 3.4, CLIENT New IP shall not include any Intellectual Property that is an improvement to or
enhancement of, any LHI Materials, LHI Background IP and/or LHI Confidential Information (collectively, “LHI Improvement IP”). For clarity, LHI Improvement IP shall be limited to any Intellectual Property which the use or commercial
exploitation by CLIENT of such Intellectual Property could not be practiced, used or commercially exploited without a license to LHI Background IP. CLIENT hereby assigns to LHI the right, title, and interest in and to any and all of such LHI
Improvement IP. 
 10.1.3        On a Statement of Work-by-Statement of Work
basis, LHI hereby assigns to CLIENT all of LHI’s right, title and interest in and to all CLIENT New IP arising from the performance of each Statement of Work hereunder, subject to CLIENT’s obligation to make all payments that become due
under such Statement of Work. If CLIENT disputes whether a particular payment is due under a Statement of Work or disputes the amount of the payment due, CLIENT may, at its option, pay the disputed payment or amount to LHI without waiving or
limiting CLIENT’s right to dispute such payment or amount and/or to seek other remedies available under this Agreement, at law or in equity, provided that CLIENT provides notice of such dispute before or concurrently with payment of such
disputed payment or amount. For the avoidance of doubt, upon payment in full of all amounts due under a particular Statement of Work (whether or not CLIENT disputes any amount paid thereunder), as between LHI and CLIENT, CLIENT shall be the
exclusive owner of all right, title and interest to all CLIENT New IP that arose under such Statement of Work, and LHI’s assignment to CLIENT of such CLIENT New IP shall be irrevocable and perpetual. 

10.1.4        LHI shall promptly disclose to CLIENT in writing all CLIENT New
IP. LHI shall execute, and shall require its personnel as well as its Affiliates, or other contractors or agents and their personnel involved in the performance of this Agreement to execute, any documents reasonably required to confirm CLIENT’s
ownership of CLIENT New IP, and any documents required to apply for, maintain and enforce any patent or other right in the CLIENT New IP. 

10.1.5        As between the Parties, LHI shall own all right, title and
interest in LHI Background IP, LHI Confidential Information and/or LHI Operating Documents. 

10.2        License Grants. 

10.2.1        During the term of this Agreement, CLIENT hereby grants to LHI a
fully paid, non-exclusive license under any CLIENT Background IP and CLIENT New IP that is necessary for LHI to perform its obligations under this Agreement for the sole and limited purpose of LHI’s performance of its obligations under this
Agreement, including, without limitation, the development of the Process and the manufacture of Product for CLIENT. CLIENT further grants to LHI a fully paid, non-exclusive, non-transferable (except in connection with the assignment of this
Agreement pursuant to Section 16.12), perpetual license, including the right to grant sublicenses, solely for contract manufacturing purposes and internal research and development, under CLIENT New IP to use, make, have made, sell, offer to
sell and import any products [...***...]. For the removal of doubt, with respect to the license granted to LHI in 
  

***Confidential Treatment Requested 

  
 17. 

 
the preceding sentence, LHI shall not have the right to grant sublicenses under the internal research and development portion of such license; provided, however, LHI shall have the right
to grant sublicenses under such license for contract manufacturing purposes. 

10.2.2        On a Statement of Work-by-Statement of Work basis, LHI hereby
grants to CLIENT a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under any and all Intellectual Property owned or Controlled by LHI (including without limitation LHI Background
IP) that LHI incorporates into any Process that is performed under each Statement of Work hereunder, to make, have made, use, sell, offer for sale, have sold and import the Product, subject to the terms set forth in Section 3.4 above and
CLIENT’s obligation to make all payments that become due under such Statement of Work. If CLIENT disputes whether a particular payment is due under a Statement of Work or disputes the amount of the payment due, CLIENT may, at its option, pay
the disputed payment or amount to LHI without waiving or limiting CLIENT’s right to dispute such payment or amount and/or to seek other remedies available under this Agreement, at law or in equity, provided that CLIENT provides notice of such
dispute before or concurrently with payment of such disputed payment or amount. For the avoidance of doubt, upon payment in full of all amounts due under a particular Statement of Work (whether or not CLIENT disputes any amount paid thereunder), the
license granted to CLIENT under this Section 10.2.2 shall be irrevocable and perpetual. 

10.3        Further Assurances. Each Party agrees to take all necessary and
proper acts, and will cause its employees, Affiliates, contractors, and consultants to take such necessary and proper acts, to effectuate the assignment and ownership provisions set forth in this Article 10. 

10.4        Prosecution of Patents. 

10.4.1        LHI will have the sole right and discretion to file, prosecute and
maintain patent applications and patents claiming LHI Background IP at LHI’s expense. 

10.4.2        CLIENT will have the sole right and discretion to file, prosecute
and maintain patent applications and patents claiming CLIENT New IP at CLIENT’s expense. LHI will cooperate with CLIENT to file, prosecute and maintain patent applications and patents claiming CLIENT New IP, and will have the right to review
and provide comments to CLIENT relating to such patent applications and patents. 

11.        REPRESENTATIONS AND WARRANTIES 

11.1        By CLIENT.    CLIENT hereby represents
and warrants to LHI that, to the best of its knowledge, (i) it has the requisite intellectual property and legal rights to provide CLIENT Deliverables, the Process, and the Product to LHI for use in the performance of LHI’s obligations
under the Statement(s) of Work, and (ii) the performance of the Statement of Work and the production by LHI of the Product as contemplated in this Agreement will not give rise to a potential cause of action by a Third Party against LHI for
infringement or another violation of intellectual property rights. Such representation and warranty will not apply to any production equipment supplied by LHI. 

  
 18. 

 11.2        By LHI. LHI
hereby represents and warrants to CLIENT that, to the best of its knowledge, (i) it or its Affiliates have the requisite intellectual property rights in its equipment, Facility and its LHI Background IP to be able to perform its obligations
under this Agreement, (ii) that LHI’s or its Affiliates’ use of its equipment, Facility, LHI Background IP and LHI Confidential Information as contemplated in this Agreement will not give rise to a potential cause of action by a Third
Party against CLIENT for infringement or another violation of intellectual property rights. LHI further warrants and covenants to CLIENT that LHI will not use any employee or consultant that has been debarred by the FDA or EMA, or, to the best of
its knowledge is subject of debarment proceedings by the FDA or EMA. 
 12.        DISCLAIMER;
LIMITATION OF LIABILITY 

12.1        DISCLAIMER.    EXCEPT FOR THE EXPRESS WARRANTIES SET
FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, WITH RESPECT TO THE PRODUCTS, MATERIALS, AND SERVICES PROVIDED UNDER THIS
AGREEMENT, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE WITH RESPECT TO SUCH PRODUCTS,
MATERIALS, OR SERVICES. 
 12.2        Disclaimer of Consequential
Damages.    EXCEPT WITH RESPECT TO A BREACH OF ARTICLE 9 OR WITH RESPECT TO EACH PARTY’S INDEMNIFICATION RIGHTS UNDER ARTICLE 14, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR
ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH THIS AGREEMENT, EVEN IF
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 12.3        Limitation of
Liability.    BOTH PARTIES HEREBY AGREE THAT TO THE FULLEST EXTENT PERMITTED BY LAW, LHI’S LIABILITY TO CLIENT, FOR ANY AND ALL INJURIES, CLAIMS, LOSSES, EXPENSES, OR DAMAGES, WHATSOEVER, ARISING OUT OF OR IN ANY WAY RELATED
TO THIS AGREEMENT FROM ANY CAUSE OR CAUSES, INCLUDING, BUT NOT LIMITED TO, NEGLIGENCE, ERRORS, OMISSIONS OR STRICT LIABILITY, SHALL NOT EXCEED THE AGGREGATE AMOUNT OF THE FEES PAID BY CLIENT UNDER THE APPLICABLE STATEMENT OF WORK GIVING RISE TO THE
CLAIM DURING THE [...***...] MONTHS IMMEDIATELY PRECEDING THE EVENT GIVING RISE TO SUCH CLAIM FOR SUCH DAMAGES, AND LHI’S LIABILITY IN CONNECTION WITH A CLAIM THAT DOES NOT ARISE FROM A PARTICULAR STATEMENT OF WORK SHALL NOT EXCEED THE
AGGREGATE AMOUNT OF THE FEES PAID BY CLIENT UNDER THIS AGREEMENT DURING THE [...***...] 
  

***Confidential Treatment Requested 

  
 19. 

 
MONTHS IMMEDIATELY PRECEDING THE EVENT GIVING RISE TO THE CLAIM FOR SUCH DAMAGES; PROVIDED, HOWEVER, THAT SUCH LIMIT SHALL NOT APPLY TO LIABILITY ARISING FROM A BREACH OF ARTICLE 9 OR
CLIENT’S CLAIM FOR INDEMNIFICATION FROM LHI PURSUANT TO SECTION 14.1. TO THE EXTENT THAT THIS CLAUSE CONFLICTS WITH ANY OTHER CLAUSE, THIS CLAUSE SHALL TAKE PRECEDENCE OVER SUCH CONFLICTING CLAUSE. IF APPLICABLE LAW PREVENTS ENFORCEMENT OF
THIS CLAUSE, THEN THIS CLAUSE SHALL BE DEEMED MODIFIED TO PROVIDE THE MAXIMUM PROTECTION FOR LHI AS IS ALLOWABLE UNDER APPLICABLE LAW. 

13.        TERM AND TERMINATION 

13.1        Term.    The term of this Agreement will
commence on the Effective Date and will continue until the fifth anniversary of the Effective Date unless terminated prior to that time or extended by the Parties. 

13.2        Termination for Material
Breach.    Either Party may terminate this Agreement, by written notice to the other Party, for any material breach of this Agreement by the other Party, if such breach is not cured within thirty (30) days after
the breaching Party receives written notice of such breach from the non-breaching Party; provided, however, that if such breach is not capable of being cured within such thirty-day period and the breaching Party has commenced and diligently
continued actions to cure such breach within such thirty-day period, except in the case of a payment default, the cure period shall be extended to 180 days, so long as the breaching Party is making diligent efforts to cure such breach. Such
termination shall be effective upon expiration of such cure period. 

13.3        Termination by Notice. 

13.3.1        Without Cause by CLIENT.    After the
first anniversary of the Effective Date, CLIENT may terminate this Agreement by providing written notice of termination no less than six months in advance of the date of termination. For the avoidance of doubt, in the event of termination by CLIENT
under this Section 13.3.1, CLIENT shall, at minimum, remain liable for all fees owed pursuant to any outstanding Statement of Work during such six-month period. 

13.3.2        Without Cause by LHI.    LHI may
terminate this Agreement by providing prior written notice of such termination to CLIENT, provided that, such termination shall not be effective until CLIENT has duly qualified an alternative supplier and a LHI Technology Transfer is completed,
further provided that such period of qualification and LHI Technology Transfer shall not exceed twelve (12) months from the date of receipt by CLIENT of LHI’s notice of termination. 

13.3.3        Termination of Clinical
Trials.    Either Party may terminate this Agreement if such Party receives notice that the production of Product hereunder or the clinical trials for which Product is being produced hereunder have been or will be
suspended or terminated by the FDA or EMA due to failure of the Product by providing written notice of termination not less than 2 months in advance of the date of termination. For the avoidance of doubt, in the event of termination by CLIENT under
this Section 13.3.3, CLIENT shall remain 

  
 20. 

 
liable for all fees actually incurred for work conducted prior to the effective date of termination (including all un-cancellable labor commitments and all work in process including all
professional services rendered through the effective date of termination), for any charges for materials that have already been purchased for the project and for any wind-down costs agreed by the Parties to be performed by LHI. LHI shall use
commercially reasonable effort to mitigate any such fees or expenses. 

13.4        Termination by Insolvency.    Either
Party may terminate this Agreement upon notice to the other Party, upon (a) the dissolution, termination of existence, liquidation or business failure of the other Party; (b) the appointment of a custodian or receiver for the other Party
who has not been terminated or dismissed within ninety (90) days of such appointment; (c) the institution by the other Party of any proceeding under national, federal or state bankruptcy, reorganization, receivership or other similar laws
affecting the rights of creditors generally or the making by such Party of a composition or any assignment for the benefit of creditors under any national, federal or state bankruptcy, reorganization, receivership or other similar law affecting the
rights of creditors generally, which proceeding is not dismissed within ninety (90) days of filing. All rights and licenses granted pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of
Title 11 of the United States Code, licenses of rights of “intellectual property” as defined therein. 

13.5        Effects of Termination. 

13.5.1        Accrued Rights.    Termination of this
Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of a Party prior to such termination. Such termination will not relieve a Party of obligations that are expressly indicated to survive the
termination of this Agreement. 
 13.5.2        Disposition of Remaining
CLIENT Property and Confidential Information.    Upon termination or expiration of this Agreement, LHI will store any Remaining CLIENT Property as set forth in Section 6.2 and, at CLIENT’s option, return or
destroy any CLIENT Confidential Information in the possession or control of LHI. Likewise, CLIENT will, at LHI’s option, return or destroy any LHI Confidential Information in the possession or control of CLIENT. Notwithstanding the foregoing
provisions: (i) LHI may retain and preserve, in a secure manner, at its sole cost and expense, samples and standards of each Product following termination or expiration of this Agreement solely for use in determining LHI’s rights and
obligations hereunder and which shall remain subject to the obligations of non-use and confidentiality set forth in this Agreement; and (ii) each Party may retain a single copy of the other Party’s Confidential Information for
documentation purposes only and which shall remain subject to the obligations of nonuse and confidentiality set forth in this Agreement. 

13.5.3        Survival.    Sections 1, 3.4, 4.7, 6.2,
9, 10, 12, 13.5, 14, 15 and 16 of this Agreement will survive any expiration or termination of this Agreement. 

14.        INDEMNIFICATION 

14.1        Indemnification of Client.    LHI will indemnify
CLIENT, its Affiliates, and their respective directors, officers, employees and agents, and defend and hold each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including

  
 21. 

 
reasonable attorneys’ fees and expenses) in connection with any and all liability suits, investigations, claims or demands (collectively, “Losses”) to the extent such Losses
arise out of or result from any claim, lawsuit or other action or threat by a Third Party arising out of: (a) any material breach by LHI of this Agreement, or (b) the gross negligence or willful misconduct on the part of one or more of the
LHI Parties in performing any activity contemplated by this Agreement, except for those Losses for which CLIENT has an obligation to indemnify the LHI Parties pursuant to Section 14.2, as to which Losses each Party will indemnify the other to
the extent of their respective liability for the Losses. 

14.2        Indemnification of LHI.    CLIENT will
indemnify LHI and its Affiliates, and their respective directors, officers, employees and agents (the “LHI Parties”), and defend and hold each of them harmless, from and against any and all Losses to the extent such Losses arise out
of or result from any claim, lawsuit or other action or threat by a Third Party arising out of: (a) any material breach by CLIENT of this Agreement, (b) the use or sale of Products (including any infringement of Third Party intellectual
property rights), except to the extent such Losses arise out of or result from (i) a breach by LHI of the Product Warranties or (ii) the use or practice of LHI Materials, LHI Background IP or LHI Confidential Information, (c) the
gross negligence or willful misconduct on the part of CLIENT or its Affiliates in performing any activity contemplated by this Agreement, or (d) the use or practice by LHI of any process, invention or other intellectual property supplied by
CLIENT to LHI under this Agreement, except for those Losses for which LHI has an obligation to indemnify CLIENT pursuant to Section 14.1, as to which Losses each Party will indemnify the other to the extent of their respective liability for the
Losses. 
 14.3        Indemnification Procedure. 

14.3.1        An “Indemnitor” means the indemnifying Party. An
“Indemnitee” means the indemnified Party, its Affiliates, and their respective directors, officers, employees and agents. 

14.3.2        An Indemnitee which intends to claim indemnification under
Section 14.1 or Section 14.2 hereof shall promptly notify the Indemnitor in writing of any claim, lawsuit or other action in respect of which the Indemnitee, its Affiliates, or any of their respective directors, officers, employees and
agents intend to claim such indemnification. The Indemnitee shall permit, and shall cause its Affiliates and their respective directors, officers, employees and agents to permit, the Indemnitor, at its discretion, to settle any such claim, lawsuit
or other action and agrees to the complete control of such defense or settlement by the Indemnitor; provided, however, that in order for the Indemnitor to exercise such rights, such settlement shall not adversely affect the Indemnitee’s
rights under this Agreement or impose any obligations on the Indemnitee in addition to those set forth herein. No such claim, lawsuit or other action shall be settled without the prior written consent of the Indemnitor and the Indemnitor shall not
be responsible for any legal fees or other costs incurred other than as provided herein. The Indemnitee, its Affiliates and their respective directors, officers, employees and agents shall cooperate fully with the Indemnitor and its legal
representatives in the investigation and defense of any claim, lawsuit or other action covered by this indemnification, all at the reasonable expense of the Indemnitor. The Indemnitee shall have the right, but not the obligation, to be represented
by counsel of its own selection and expense. 

  
 22. 

14.4        Insurance.    CLIENT will maintain, at
all times during the clinical use (including any follow-up period as specified in the applicable clinical protocol) of Product manufactured by LHI under this Agreement, a products liability insurance policy (the “Insurance Policy”),
with a per occurrence limit of at least five million dollars ($5,000,000) and an aggregate limit of at least five million dollars ($5,000,000), and will provide a Certificate of Insurance to LHI that the Insurance Policy has been endorsed to
designate LHI as an additional insured. Notwithstanding the foregoing, if the Insurance Policy is a claims based policy, CLIENT shall maintain such Insurance Policy for an additional five year period after clinical use (including any follow-up
period as specified in the applicable clinical protocol). CLIENT will maintain the Insurance Policy with an insurance company having a minimum AM Best rating of A and that is licensed to do business in the State of Maryland. CLIENT will provide LHI
with at least 30 days’ written notice prior to termination of such Insurance Policy. 

15.        ADDITIONAL COVENANTS 

15.1        Non-Solicitation.    During the term of this
Agreement and for two (2) years thereafter, each of the Parties agrees not to seek to induce or solicit any employee of the other Party or its Affiliates to discontinue his or her employment with the other Party or its Affiliate in order to
become an employee or an independent contractor of the soliciting Party or its Affiliate; provided, however, that neither Party shall be in violation of this Section 15.1 as a result of making a general solicitation for employees or
independent contractors. For the avoidance of doubt, the publication of an advertisement shall not constitute solicitation or inducement. 

15.2        Commercial Scale Manufacture.    In the
event that CLIENT desires to commence commercial scale manufacture of Product, the Parties agree to negotiate in good faith a definitive agreement for the provision of such manufacturing services to CLIENT by LHI (a “Definitive
Agreement”). As of the Effective Date, the Parties outlined certain non-binding terms set forth in that certain Non-Binding Term Sheet by and between CLIENT and LHI dated July 6, 2012, and if CLIENT desires to commence commercial scale
manufacture of Product, the Parties agree to further discuss and negotiate such non-binding terms in the course of negotiating in good faith a Definitive Agreement. 

16.        MISCELLANEOUS 

16.1        Independent Contractors.    Each of the
Parties is an independent contractor and nothing herein contained shall be deemed to constitute the relationship of partners, joint venturers, nor of principal and agent between the Parties. Neither Party shall at any time enter into, incur, or hold
itself out to Third Parties as having authority to enter into or incur, on behalf of the other Party, any commitment, expense, or liability whatsoever. 

16.2        Force Majeure.    Neither Party shall be
in breach of this Agreement if there is any failure of performance under this Agreement (except for payment of any amounts due under this Agreement) occasioned by any reason beyond the control and without the fault or negligence of the Party
affected thereby, including, without limitation, an act of God, fire, flood, act of government or state, war, civil commotion, insurrection, acts of terrorism, embargo, sabotage, prevention from or hindrance in obtaining energy or other utilities, a
shortage of raw materials or other necessary components , labor disputes of whatever nature, or any other reason beyond the control and without the fault or negligence of the Party affected thereby (a “Force Majeure

  
 23. 

 
Event”). Such excuse shall continue as long as the Force Majeure Event continues. Upon cessation of such Force Majeure Event, the affected Party shall promptly resume performance
under this Agreement as soon as it is commercially reasonable for the Party to do so. Each Party agrees to give the other Party prompt written notice of the occurrence of any Force Majeure Event, the nature thereof, and the extent to which the
affected Party will be unable to fully perform its obligations under this Agreement. Each Party further agrees to use commercially reasonable efforts to correct the Force Majeure Event as quickly as practicable (provided that in no event shall a
Party be required to settle any labor dispute) and to give the other Party prompt written notice when it is again fully able to perform such obligations. In the event that a Force Majeure Event continues for more than one hundred eighty
(180) consecutive days, the Party not affected by such Force Majeure Event shall have the right to terminate this Agreement upon written notice to the other Party. 

16.3        Condemnation.    If the Facility is
condemned or taken as a result of the exercise of the power of eminent domain or will be conveyed to a governmental agency having power of eminent domain under the threat of the exercise of such power (any of the foregoing, a
“Condemnation”), then this Agreement will terminate as of the date on which title to the Facility vests in the authority so exercising or threatening to exercise such power and CLIENT will not have any right to the Condemnation proceeds.

 16.4        Notices.    Any notice required or
permitted to be given under this Agreement by any Party shall be in writing and shall be (a) delivered personally, (b) sent by registered mail, return receipt requested, postage prepaid, (c) sent by a nationally-recognized courier
service guaranteeing next-day or second day delivery, charges prepaid, or (d) delivered by facsimile (with documented evidence of transmission), to the addresses or facsimile numbers of the other Party set forth below, or at such other
addresses as may from time to time be furnished by similar notice by any Party. The effective date of any notice under this Agreement shall be the date of receipt by the receiving Party. 

If to LHI: 

Lonza Houston, Inc. 

Attn: Business Head 

8066 El Rio St. 

Houston, TX 77056 

E-mail: [...***...]@lonza.com 

With a copy to: 

Assistant General Counsel 

Lonza America, Inc. 

90 Boroline Road 

Allendale, NJ 07401 

Fax: (201) 378-5630 
  

***Confidential Treatment Requested 

  
 24. 

 If to Client: 

Celladon Corporation 

Attn: Rebecque Laba, VP Finance and Administration 

12760 High Bluff Drive, Suite 240 

San Diego, CA 92130-2019 

Fax: (858) 964-0974 

Either Party may change its address for notice by giving notice thereof in the manner set forth in this Section 16.4. 

16.5        Entire Agreement; Amendments.    This
Agreement, together with the Quality Agreement, all SOWs entered into pursuant to the Original MSA prior to the Restatement Date, and that certain letter agreement between the Parties dated as of the Restatement Date, constitutes the full
understanding of the Parties and a complete and exclusive statement of the terms of their agreement with respect to the specific subject matter hereof and supersedes all prior agreements and understandings, oral and written, among the Parties with
respect to the subject matter hereof or thereof, including, without limitation, the Original MSA. All SOWs entered into pursuant to the Original MSA prior to the Restatement Date shall be deemed to have been entered into pursuant to this Agreement
and shall be subject in all respects to the terms and conditions of this Agreement, and all other events and activities that occurred prior to the Restatement Date under, or pursuant to, or that were subject to, the Original MSA shall be deemed to
have occurred under and pursuant to, and to have been subject to, this Agreement. No terms, conditions, understandings or agreements purporting to amend, modify or vary the terms of this Agreement or any SOW shall be binding unless hereafter made in
a written instrument referencing this Agreement and signed by each of the Parties. 

16.6        Governing Law.    The construction,
validity and performance of the Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without giving effect to its conflicts of laws provisions. 

16.7        Counterparts.    This Agreement and any
amendment hereto may be executed in any number of counterparts, each of which shall for all purposes be deemed an original and all of which shall constitute the same instrument. This Agreement shall be effective upon full execution by facsimile or
original, and a facsimile signature shall be deemed to be and shall be as effective as an original signature. 

16.8        Severability.    If any part of this
Agreement shall be found to be invalid or unenforceable under applicable law in any jurisdiction, such part shall be ineffective only to the extent of such invalidity or unenforceability in such jurisdiction, without in any way affecting the
remaining parts of this Agreement in that jurisdiction or the validity or enforceability of the Agreement as a whole in any other jurisdiction. In addition, the part that is ineffective shall be reformed in a mutually agreeable manner so as to as
nearly approximate the intent of the Parties as possible. 
 16.9        Titles
and Subtitles.    All headings, titles and subtitles used in this Agreement or any SOW are for convenience only and are not to be considered in construing or interpreting any term or provision of this Agreement or any
SOW. 

  
 25. 

16.10        Recitals.    All “RECITALS”
set forth on the first page of this Agreement form an integral part of this Agreement and are incorporated into this Agreement by this reference. 

16.11        Pronouns.    Where the context
requires, (i) all pronouns used herein will be deemed to refer to the masculine, feminine or neuter gender as the context requires, and (ii) the singular context will include the plural and vice versa. 

16.12        Assignment.    This Agreement shall be binding
upon the successors and assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of its successors and assigns. Neither Party may assign its interest under this Agreement without the prior written consent
of the other Party, such consent not to be unreasonably withheld; provided, however, that either Party may assign this Agreement to an Affiliate of such Party provided that the assigning Party guarantees the obligations, including all payment
obligations, of the assignee; and provided, further, that either Party may assign this Agreement to a successor in interest by way of merger, acquisition, consolidation, or sale of all or substantially all of the business of such Party to which this
Agreement relates, provided that in the event that CLIENT merges, is acquired, consolidates or sells all or substantially all of its business to which this Agreement relates, such successor in interest is not an entity whose business primarily
derives from providing contract manufacturing services. Any permitted assignment of this Agreement by either Party will be conditioned upon that Party’s permitted assignee agreeing in writing to comply with all the terms and conditions
contained in this Agreement. Any purported assignment without a required consent shall be void. No assignment shall relieve any Party of responsibility for the performance of any obligation that accrued prior to the effective date of such
assignment. 
 16.13        Waiver.    The failure of any
Party at any time or times to require performance of any provision of this Agreement or any SOW will in no manner affect its rights at a later time to enforce the same. No waiver by any Party of any term, provision or condition contained in this
Agreement or any SOW, whether by conduct or otherwise, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other term, provision or condition of this
Agreement or any SOW. 
 16.14        Dispute
Resolution.    Other than disputes under Section 5.4, if the Parties are unable to resolve a dispute, despite its good faith efforts, either Party may refer the dispute to the President of each Party’s
respective business unit (or other designee). In the event that no agreement is reached by the Presidents (or other designee of its President) with respect to such dispute within thirty (30) days after its referral to them, either Party may
pursue any and all remedies available at law or in equity. 
 16.15        No
Presumption Against Drafter.    For purposes of this Agreement, each Party hereby waives any rule of construction that requires that ambiguities in this Agreement or any SOW be construed against the drafter. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 26. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date last signed by the parties hereto. 
  

					
		 	 CELLADON CORPORATION

			
	     August 26, 2013        
	 	 By:
	 	 /s/ Krisztina M. Zsebo

	 Date
	 		 	 Name: Krisztina M. Zsebo, PhD

		 		 	 Title:        President & CEO

		
		 	 LONZA HOUSTON, INC.

			
	     August 26, 2013        
	 	 By:
	 	 /s/ J. David Enloe, Jr.

	 Date
	 		 	 Name: J. David Enloe, Jr.

		 		 	 Title:        Head, Viral-based Therapeutics

  
 27.EX-10.7

 Exhibit 10.7 

STOCKHOLDERS AGREEMENT 

BY AND AMONG 

SPRINGLEAF HOLDINGS, INC. 

AND 
 SPRINGLEAF
FINANCIAL HOLDINGS, LLC 
  
  

Dated as of                     , 2013

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	
	ARTICLE I	  
	
	DEFINITIONS	  
	 Section 1.1
	  	Certain Defined Terms	  	 	1	  
	 Section 1.2
	  	Construction	  	 	5	  
	
	ARTICLE II	  
	
	TRANSFER	  
	 Section 2.1
	  	Binding Effect on Transferees	  	 	6	  
	 Section 2.2
	  	Additional Purchases	  	 	6	  
	 Section 2.3
	  	Charter Provisions	  	 	6	  
	 Section 2.4
	  	Legend	  	 	6	  
	
	ARTICLE III	  
	
	BOARD OF DIRECTORS	  
	 Section 3.1
	  	Board	  	 	7	  
	 Section 3.2
	  	Committees	  	 	8	  
	 Section 3.3
	  	Observers	  			
	
	ARTICLE IV	  
	
	REGISTRATION RIGHTS	  
	 Section 4.1
	  	Demand Registration	  	 	9	  
	 Section 4.2
	  	Piggyback Registrations	  	 	11	  
	 Section 4.3
	  	Shelf Registration	  	 	12	  
	 Section 4.4
	  	Withdrawal Rights	  	 	14	  
	 Section 4.5
	  	Registration Procedures	  	 	14	  
	 Section 4.6
	  	Registration Expenses	  	 	20	  
	
	ARTICLE V	  
	
	INDEMNIFICATION	  
	 Section 5.1
	  	General Indemnification	  	 	21	  
	 Section 5.2
	  	Registration Statement Indemnification	  	 	21	  
	 Section 5.3
	  	Contribution	  	 	22	  
	 Section 5.4
	  	Procedure	  	 	23	  
	 Section 5.5
	  	Other Matters	  	 	23	  

  
 i 

							
	
	ARTICLE VI	  
	
	MISCELLANEOUS	  
	 Section 6.1
	  	Headings	  	 	24	  
	 Section 6.2
	  	Entire Agreement	  	 	24	  
	 Section 6.3
	  	Further Actions; Cooperation	  	 	24	  
	 Section 6.4
	  	Notices	  	 	25	  
	 Section 6.5
	  	Applicable Law	  	 	25	  
	 Section 6.6
	  	Severability	  	 	25	  
	 Section 6.7
	  	Successors and Assigns	  	 	26	  
	 Section 6.8
	  	Amendments	  	 	26	  
	 Section 6.9
	  	Waiver	  	 	26	  
	 Section 6.10
	  	Counterparts	  	 	26	  
	 Section 6.11
	  	Submission To Jurisdiction	  	 	26	  
	 Section 6.12
	  	Injunctive Relief	  	 	27	  
	 Section 6.13
	  	Recapitalizations, Exchanges, Etc. Affecting the Shares of Common Stock; New Issuance	  	 	27	  
	 Section 6.14
	  	Termination	  	 	27	  
	 Section 6.15
	  	Third Party Beneficiary	  	 	28	  
	 Section 6.16
	  	Rule 144	  			
	 Section 6.17
	  	Information	  			

  
 ii 

 STOCKHOLDERS AGREEMENT 

THIS STOCKHOLDERS AGREEMENT (this “Agreement”) is made as of
                     , 2013, by and between Springleaf Financial Holdings, LLC, a Delaware limited liability company (the “Initial
Stockholder”) and Springleaf Holdings, Inc., a Delaware corporation (the “Company”). Unless otherwise indicated, references to articles and sections shall be to articles and sections of this Agreement. 

WHEREAS, the Initial Stockholder is a holder of shares of Common Stock (as hereinafter defined); and 

WHEREAS, the Company has agreed to provide the registration rights and other rights set forth herein. 

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein and for good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows: 
 ARTICLE I

 DEFINITIONS 

Section 1.1 Certain Defined Terms. For purposes of this Agreement, the following terms shall have the following meanings: 

(a) “Actions” shall have the meaning assigned to it in Section 5.1(a). 

(b) “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated under the Exchange Act; provided that no Stockholder
shall be deemed an Affiliate of any other Stockholder solely by reason of any investment in the Company. 
 (c) “Agreement” shall
have the meaning assigned to it in the preamble. 
 (d) A Person shall be deemed to “Beneficially Own” securities if such Person
is deemed to be a “beneficial owner” within the meaning of Rules 13d-3 and 13d-5 under the Exchange Act as in effect on the date of this Agreement. 

(e) “Board” shall mean the board of directors of the Company. 

(f) “Bylaws” shall mean the bylaws of the Company, as may be amended and/or restated from time to time. 

(g) “Certificate of Incorporation” shall mean the certificate of incorporation of the Company, as may be amended and/or restated
from time to time. 

 (h) “Commission” shall mean the United States Securities and Exchange Commission or
any successor agency. 
 (i) “Common Stock” shall mean the Company’s common stock, par value $0.01 per share, and any and
all securities of any kind whatsoever of the Company which may be issued and outstanding on or after the date hereof in respect of, in exchange for, or upon conversion of shares of Common Stock pursuant to a merger, consolidation, stock split, stock
dividend, recapitalization of the Company or otherwise. 
 (j) “Company” shall have the meaning assigned to it in preamble. 

(k) “Company Securities” shall mean (i) any Common Stock and (ii) any other securities of the Company entitled to vote
generally in the election of directors of the Company. 
 (l) “Demand” shall have the meaning assigned to it in
Section 4.1(a). 
 (m) “Demand Registration” shall have the meaning assigned to it in Section 4.1(a). 

(n) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. 
 (o) “FIG” shall mean Fortress Investment Group LLC, a Delaware limited liability company. 

(p) “FIG LLC” shall mean FIG LLC, a Delaware limited liability company, or any other Person designated as “FIG LLC” by
FIG in a written notice to the Company. 
 (q) “Filings” shall mean annual, quarterly and current reports and other documents
filed or furnished by the Company or any Subsidiary of the Company under the Exchange Act; annual reports to stockholders, annual and quarterly statutory statements of the Company or any Subsidiary of the Company; and any registration statements,
prospectuses documents filed or furnished by the Company or any of its Subsidiaries under the Securities Act (other than any registration statement, any Issuer Free Writing Prospectus, any prospectus or preliminary prospectus or any amendment
thereof or supplement thereto to the extent that Section 5.2 of this Agreement applies). 
 (r) “FINRA” shall mean the
Financial Industry Regulatory Authority. 
 (s) “Fortress Affiliate Stockholder” shall mean (A) any director of the Company
who may be deemed an Affiliate of FIG, (B) any director or officer of FIG and (C) any investment funds (including any managed accounts) managed directly or indirectly by FIG or its Affiliates. 

(t) “Form S-3” shall have the meaning assigned to it in Section 4.3(a). 

  
 2 

 (u) “Free Writing Prospectus” shall mean a free writing prospectus, as defined in Rule
405 under the Securities Act. 
 (v) “Initial Public Offering” shall mean the initial public offering of Common Stock pursuant to
an effective registration statement under the Securities Act. 
 (w) “Initial Stockholder” shall have the meaning assigned to it
in preamble. 
 (x) “Inspectors” shall have the meaning assigned to it in Section 4.5(a)(viii). 

(y) “IPO Underwriting Agreement” shall mean the underwriting agreement, dated
                     , 2013, between the Company and the underwriters named therein. 

(z) “Issuer Free Writing Prospectus” shall mean an issuer free writing prospectus, as defined in Rule 433 under the Securities Act.

 (aa) “Losses” shall have the meaning assigned to it in Section 5.1(a). 

(bb) “Offering Expenses” shall have the meaning assigned to it in Section 4.6(a). 

(cc) “Other Demanding Sellers” shall have the meaning assigned to it in Section 4.2(b). 

(dd) “Other Proposed Sellers” shall have the meaning assigned to it in Section 4.2(b). 

(ee) “Permitted Transferee” shall mean, with respect to each Stockholder, (i) any other Stockholder, (ii) such
Stockholder’s Affiliates, (iii) in the case of any Stockholder, (A) any member or general or limited partner of such Stockholder (including any member of the Initial Stockholder), (B) any corporation, partnership, limited
liability company or other entity that is an Affiliate of such Stockholder or any member, general or limited partner of such Stockholder (collectively, “Stockholder Affiliates”), (C) any investment funds managed directly or indirectly
by such Stockholder or any Stockholder Affiliate (a “Stockholder Fund”), (D) any general or limited partner of any Stockholder Fund, (E) any managing director, general partner, director, limited partner, officer or employee of
any Stockholder Affiliate, or any spouse, lineal descendant, sibling, parent, heir, executor, administrator, testamentary trustee, legatee or beneficiary of any of the foregoing persons described in this clause (E) (collectively,
“Stockholder Associates”) or (F) any trust, the beneficiaries of which, or any corporation, limited liability company or partnership, the stockholders, members or general or limited partners of which, consist solely of any one or more
of such Stockholder, any general or limited partner of such Stockholder, any Stockholder Affiliates, any Stockholder Fund, any Stockholder Associates, their spouses or their lineal descendants and (iv) any other Person that acquires shares of
Common Stock from such Stockholder other than pursuant to a Public Offering and that agrees to become party to or be bound by this Agreement. 

  
 3 

 (ff) “Person” shall mean any individual, firm, corporation, partnership, limited
liability company or other entity, and shall include any successor (by merger or otherwise) of such entity. 
 (gg) “Piggyback
Notice” shall have the meaning assigned to it in Section 4.2(a). 
 (hh) “Piggyback Registration” shall have the
meaning assigned to it in Section 4.2(a). 
 (ii) “Piggyback Seller” shall have the meaning assigned to it in
Section 4.2(a). 
 (jj) “Public Offering” shall mean an offering of equity securities of the Company pursuant to an
effective registration statement under the Securities Act, including an offering in which Stockholders are entitled to sell Common Stock pursuant to the terms of this Agreement. 

(kk) “Records” shall have the meaning assigned to it in Section 4.5(a)(viii). 

(ll) “Registrable Amount” shall mean a number of shares of Common Stock equal to 1% of the Common Stock issued and outstanding
immediately after the consummation of the Initial Public Offering. 
 (mm) “Registrable Securities” shall mean any Common Stock
currently owned or hereafter acquired by any Stockholder. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when (x) a registration statement registering such securities under the Securities
Act has been declared effective and such securities have been sold or otherwise transferred by the holder thereof pursuant to such effective registration statement or (y) such securities are sold in accordance with Rule 144 (or any successor
provision) promulgated under the Securities Act. 
 (nn) “Registration Expenses” shall have the meaning assigned to it in
Section 4.6(a). 
 (oo) “Requesting Stockholder” shall have the meaning assigned to it in Section 4.1(a). 

(pp) “Securities Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

(qq) “Selling Holders” shall have the meaning assigned to it in Section 4.5(a)(i). 

(rr) “Shelf Notice” shall have the meaning assigned to it in Section 4.3(a). 

(ss) “Shelf Registration Effectiveness Period” shall have the meaning assigned to it in Section 4.3(c). 

  
 4 

 (tt) “Shelf Registration Statement” shall have the meaning assigned to it in
Section 4.3(a). 
 (uu) “Shelf Underwritten Offering” shall have the meaning assigned to it in Section 4.3(f). 

(vv) “Stockholders” shall mean (i) the Initial Stockholder, (ii) each Fortress Affiliate Stockholder and (iii) each
Permitted Transferee who becomes a party to or bound by the provisions of this Agreement in accordance with the terms hereof or a Permitted Transferee thereof who is entitled to enforce the provisions of this Agreement in accordance with the terms
hereof, in each case of clauses (i), (ii) and (iii) to the extent that the Initial Stockholder, Fortress Affiliate Stockholders and Permitted Transferees, together, hold of record or Beneficially Own at least a Registrable Amount; provided
that solely for purposes of determining the number of directors FIG LLC has the right to designate pursuant to Section 3.1(a), FIG LLC shall be deemed to hold of record or Beneficially Own a number of Company Securities equal to the product of
(x) the total number of Company Securities held of record or Beneficially Owned by the Initial Stockholder and (y) a fraction, the numerator of which is the total number of voting securities of the Initial Stockholder held of record or
beneficially owned by FIG LLC and the Fortress Affiliate Stockholders and the denominator of which is the total number of voting securities of the Initial Stockholder then issued and outstanding. 

(ww) “Subsidiary” shall mean with respect to any Person (i) a corporation, fifty percent (50%) or more of the voting or
capital stock of which is, as of the time in question, directly or indirectly owned by such Person, (ii) any other partnership, joint venture, association, joint stock company, trust, unincorporated organization or other entity in which such
Person, directly or indirectly, owns fifty percent (50%) or more of the equity economic interest thereof or has the power to elect or direct the election of fifty percent (50%) or more of the members of the governing body of such entity or
otherwise has control over such entity (e.g., as the managing partner of a partnership), or (iii) which would be considered subsidiaries of such Person within the meaning of Regulation S-K or Regulation S-X. 

(xx) “Suspension Period” shall have the meaning assigned to it in Section 4.3(d). 

(yy) “Underwritten Offering” shall mean a sale of securities of the Company to an underwriter or underwriters for reoffering to the
public. 
 (zz) “Voting Power of the Company” shall mean the voting power of the then issued and outstanding capital stock of the
Company entitled to vote in the election of directors of the Company. 
 Section 1.2 Construction. For the purposes of this
Agreement (i) words (including capitalized terms defined herein) in the singular shall be held to include the plural and vice versa and words (including capitalized terms defined herein) of one gender shall be held to include the other gender
as the context requires, (ii) the terms “hereof,” “herein” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular
provision of this Agreement, and Article and Section references are to Articles and Sections of this Agreement, unless otherwise specified, 

  
 5 

 
(iii) the word “including” and words of similar import when used in this Agreement shall mean “including, without limitation,” (iv) all references to any period of
days shall be deemed to be to the relevant number of calendar days unless otherwise specified, and (v) all references herein to “$” or dollars shall refer to United States dollars, unless otherwise specified. 

ARTICLE II 
 TRANSFER

 Section 2.1 Binding Effect on Transferees. A Permitted Transferee shall become a Stockholder hereunder, without any
further action by the Company, following a transfer by a Stockholder of Company Securities to such Permitted Transferee upon the execution by such Permitted Transferee of a joinder providing that such Person shall be bound by and shall fully comply
with the terms of this Agreement (including the provisions of Article IV with respect to the Company Securities being transferred to such transferee). The Fortress Affiliate Stockholders shall be deemed to be Stockholders without any further action.

 Section 2.2 Additional Purchases. Any Company Securities owned by a Stockholder on or after the date of this Agreement shall
have the benefit of and be subject to the terms and conditions of this Agreement. 
 Section 2.3 Charter Provisions. The parties
hereto shall use their respective reasonable efforts (including voting or causing to be voted all of the Company Securities held of record by such party or Beneficially Owned by such party by virtue of having voting power over such Company
Securities) so as to cause no amendment to be made to the Certificate of Incorporation or Bylaws as in effect as of the date of this Agreement in a manner that would (a) add restrictions to the transferability of the Company Securities by the
Initial Stockholder, any Fortress Affiliate Stockholder or their Permitted Transferees who remain a “Stockholder” (as such term is used herein) at the time of such an amendment, which restrictions are beyond those then provided for in the
Certificate of Incorporation, this Agreement or applicable securities laws or (b) nullify any of the rights of the Initial Stockholder, any Fortress Affiliate Stockholder or their Permitted Transferees who remain a “Stockholder” (as
such term is used herein) at the time of such amendment, which rights are explicitly provided for in this Agreement, unless, in each such case, such amendment shall have been approved by such Stockholder. 

Section 2.4 Legend. Any certificate representing Company Securities issued to a Stockholder shall be stamped or otherwise
imprinted with a legend in substantially the following form: 
 “The shares represented by this certificate are subject to the
provisions contained in the Stockholders Agreement, dated as of                      , 2013, by and among Springleaf Holdings, Inc. and the
stockholder of Springleaf Holdings, Inc. described therein.” 
 The Company shall make customary arrangements to cause any Company Securities issued in
uncertificated form to be identified on the books of the Company in a substantially similar manner. 

  
 6 

 ARTICLE III 

BOARD OF DIRECTORS 

Section 3.1 Board. 

(a) For so long as this Agreement is in effect, the Company and each Stockholder shall take all reasonable actions within their respective
control (including voting or causing to be voted all of the Company Securities held of record by such Stockholder or Beneficially Owned by such Stockholder by virtue of having voting power over such Company Securities, and, with respect to the
Company, as provided in Sections 3.1(c) and (d)) so as to cause to be elected to the Board, and to cause to continue in office, not more than five directors (or such other number of directors as FIG LLC may agree to in writing), at any given time:

 (i) a number of directors equal to a majority of the Board, plus one director, shall be individuals designated by FIG
LLC, for so long as the Stockholders, together, have Beneficial Ownership of at least 30% of the Voting Power of the Company; 

(ii) a number of directors equal to a majority of the Board, minus one director, shall be individuals designated by FIG LLC,
for so long as the Stockholders, together, have Beneficial Ownership of less than 30% but at least 20% of the Voting Power of the Company, provided that if the Board consists of six or fewer directors, then the Initial Stockholder shall have the
right to designate a number of directors equal to three directors; 
 (iii) a number of directors (rounded up to the nearest
whole number) that would be required to maintain the Initial Stockholder’s proportional representation on the Board shall be individuals designated by FIG LLC, for so long as the Stockholders, together, have Beneficial Ownership of less than
20% but at least 10% of the Voting Power of the Company, provided that if the Board consists of six or fewer directors, then the Initial Stockholder shall have the right to designate a number of directors equal to two directors; and 

(iv) a number of directors (rounded up to the nearest whole number) that would be required to maintain the Initial
Stockholder’s proportional representation on the Board shall be individuals designated by FIG LLC, for so long as the Stockholders, together, have Beneficial Ownership of less than 10% but at least 5% of the Voting Power of the Company,
provided that if the Board consists of six or fewer directors, then the Initial Stockholder shall have the right to designate a number of directors equal to one director. 

(b) If FIG LLC notifies the Stockholders of its desire to remove, with or without cause, any director previously designated by it, the
Stockholders shall vote or cause to be voted all of the shares of Company Securities held of record by such Stockholders or Beneficially Owned by such Stockholders by virtue of having voting power over such Company Securities and take all other
reasonable actions within its control to cause the removal of such director. 

  
 7 

 (c) The Company agrees to include in the slate of nominees recommended by the Board those
persons designated by FIG LLC in accordance with Section 3.1(a) and to use its reasonable best efforts to cause the election of each such designee to the Board, including nominating such designees to be elected as directors, in each case
subject to applicable law. 
 (d) In the event that a vacancy is created at any time by the death, disability, retirement, resignation or
removal of any director who is designated by FIG LLC in accordance with Section 3.1(a), the Company agrees to take at any time and from time to time all actions necessary to cause the vacancy created thereby to be filled as promptly as
practicable by a new designee of FIG LLC. In the event that the size of the Board is expanded to more than six directors, the Company agrees to take at any time and from time to time all actions necessary to cause the Board to continue to have the
number of FIG LLC’s designees that corresponds to the requirements of Section 3.1(a). 
 (e) In the event that at any time the
number of directors entitled to be designated by FIG LLC pursuant to Section 3.1(a) decreases, the Initial Stockholder and its Permitted Transferee shall take reasonable actions to cause a sufficient number of designated directors to resign
from the Board at or prior to the end of such designated director’s term such that the number of designated directors after such resignation(s) equals the number of directors the Initial Stockholder would have been entitled to designate
pursuant to Section 3.1(a). Any vacancies created by such resignation may remain vacant until the next annual meeting of stockholders or filled by a majority vote of the Board. Notwithstanding the foregoing, such designated director(s) need not
resign from the Board at or prior to the end of such director’s term if the Company’s nominating committee recommends the nomination of such director(s) for election at the next annual meeting coinciding with the end of such
director’s term, or otherwise (and for the avoidance of doubt, such director shall no longer be considered a designee of FIG LLC). 

Section 3.2 Committees. For so long as this Agreement is in effect, the Company shall take all reasonable actions within its
control at any given time so as to cause to be appointed to any committee of the Board a number of directors designated by FIG LLC that is up to the number of directors that is proportionate (rounding up to the next whole director) to the
representation that FIG LLC is entitled to designate to the Board under this Agreement, to the extent such directors are permitted to serve on such committees under the applicable rules of the Commission and the New York Stock Exchange
(“NYSE”) or by any other applicable stock exchange. It is understood by the parties hereto that FIG LLC shall not be required to have its directors represented on any committee and any failure to exercise such right in this section in a
prior period shall not constitute any waiver of such right in a subsequent period. 
 3.3 Observer. For so long as the Stockholders,
together, have Beneficial Ownership of at least 10% of the Voting Power of the Company, the Initial Stockholder shall have the right to appoint a non-voting representative (the “Observer”) to attend (at the Observer’s sole
option, in person or telephonically) all meetings of the Board (and all committees thereof other than the compensation and audit committees), to change the Observer so appointed at any time and, upon the resignation of the Observer for any reason,
to reappoint another Observer. In addition, the Company shall provide the Observer with copies of all notices, consents, resolutions, minutes or other written materials provided to the Board (and to any committee thereof other than the compensation
and audit committees) at the same time and in the same manner such materials are circulated to the Board (and to any committee thereof other than the compensation and audit committees); provided that such Observer shall execute and deliver to the
Company a confidentiality agreement in a form reasonably satisfactory to the Company prior to receiving such information; provided further that the Observer may share all information received or observed in his or her capacity as an Observer with
FIG and AIG Capital and their respective Affiliates, including their advisors. Any action taken by the Board at any meeting will not be invalidated by the absence of the Observer at such meeting. 

  
 8 

 ARTICLE IV 

REGISTRATION RIGHTS 

Section 4.1 Demand Registration. 

(a) At any time after the date that is 180 days after the date hereof (or such earlier date (i) as would permit the Company to
cause any filings required hereunder to be filed on the 180th day after the date hereof or (ii) as is permitted by waiver under the IPO Underwriting Agreement), any Person that is a
Stockholder (a “Requesting Stockholder”) on the date a Demand is made shall be entitled to make a written request of the Company (a “Demand”) for registration under the Securities Act of a number of Registrable
Securities that, when taken together with the number of Registrable Securities requested to be registered under the Securities Act by such Requesting Stockholder’s Affiliates, equals or is greater than the Registrable Amount (a “Demand
Registration”) and thereupon the Company will, subject to the terms of this Agreement, use its commercially reasonable efforts to effect the registration under the Securities Act of: 

(i) the Registrable Securities which the Company has been so requested to register by the Requesting Stockholders for
disposition in accordance with the intended method of disposition stated in such Demand, which may be an Underwritten Offering; 

(ii) all other Registrable Securities which the Company has been requested to register pursuant to Section 4.1(b); and

 (iii) all shares of Common Stock which the Company may elect to register in connection with any offering of Registrable
Securities pursuant to this Section 4.1, but subject to Section 4.1(f); 
 all to the extent necessary to permit the disposition
(in accordance with the intended methods thereof) of the Registrable Securities and the additional Common Stock, if any, to be so registered. 

(b) A Demand shall specify: (i) the aggregate number of Registrable Securities requested to be registered in such Demand Registration,
(ii) the intended method of disposition in connection with such Demand Registration, to the extent then known and (iii) the identity of the Requesting Stockholder (or Requesting Stockholders). Within five days after receipt of a Demand,
the Company shall give written notice of such Demand to any other Persons that on the date a Demand is delivered to the Company is a Stockholder (excluding Fortress Affiliate Stockholders which have not signed a joinder as contemplated by Section
2.1). Subject to Section 4.1(f), the Company shall include in the Demand Registration covered by such Demand all Registrable Securities with respect to which the Company has received a written request for inclusion therein. Such written request
shall comply with the requirements of a Demand as set forth in this Section 4.1(b). 
 (c) Each Stockholder shall be entitled to an
unlimited number of Demand Registrations until such time as the Stockholders, together, Beneficially Own less than a Registrable Amount. 

  
 9 

 (d) Demand Registrations shall be on such registration form of the Commission for which the
Company is eligible as shall be selected by the Requesting Stockholders whose shares represent a majority of the Registrable Securities that the Company has been requested to register, including, to the extent permissible, an automatically effective
registration statement or an existing effective registration statement filed by the Company with the Commission, and shall be reasonably acceptable to the Company. 

(e) The Company shall not be obligated to effect any Demand Registration (A) within one month of a “firm commitment”
Underwritten Offering in which all Stockholders were given “piggyback” rights pursuant to Section 4.2 (subject to Section 4.1(f)) and provided that at least 50% of the number of Registrable Securities requested by such
Stockholders to be included in such Demand Registration were included) or (B) within one month of any other Underwritten Offering pursuant to Section 4.3(e). In addition, the Company shall be entitled to postpone (upon written notice to
all Stockholders) for a reasonable period of time not to exceed 60 days in succession the filing or the effectiveness of a registration statement for any Demand Registration (but no more than twice, or for more than 90 days in the
aggregate, in any period of 12 consecutive months) if the Board determines in good faith and in its reasonable judgment that the filing or effectiveness of the registration statement relating to such Demand Registration would cause the disclosure of
material, non-public information that the Company has a bona fide business purpose for preserving as confidential. In the event of a postponement by the Company of the filing or effectiveness of a registration statement for a Demand Registration,
the holders of a majority of Registrable Securities held by the Requesting Stockholder(s) shall have the right to withdraw such Demand in accordance with Section 4.4. 

(f) The Company shall not include any securities other than Registrable Securities in a Demand Registration, except with the written consent
of Stockholders participating in such Demand Registration that hold a majority of the Registrable Securities included in such Demand Registration. If, in connection with a Demand Registration, any managing underwriter (or, if such Demand
Registration is not an Underwritten Offering, a nationally recognized investment bank engaged in connection with such Demand Registration) advises the Company, that, in its opinion, the inclusion of all of the securities, including securities of the
Company that are not Registrable Securities, sought to be registered in connection with such Demand Registration would adversely affect the marketability of the Registrable Securities sought to be sold pursuant thereto, then the Company shall
include in such registration statement only such securities as the Company is advised by such underwriter or investment bank can be sold without such adverse effect as follows and in the following order of priority: (i) first, up to the number
of Registrable Securities requested to be included in such Demand Registration by the Stockholders, which, in the opinion of the underwriter can be sold without adversely affecting the marketability of the offering, pro rata among such Stockholders
requesting such Demand Registration on the basis of the number of such securities held by such Stockholders and such Stockholders that are Piggyback Sellers; (ii) second, securities the Company proposes to sell; and (iii) third, all other
securities of the Company duly requested to be included in such registration statement, pro rata on the basis of the number of such other securities requested to be included or such other method determined by the Company. 

(g) Any investment bank(s) that will serve as an underwriter with respect to such Demand Registration or, if such Demand Registration is not
an Underwritten Offering, 

  
 10 

 
any investment bank engaged in connection therewith, shall be selected (i) by FIG LLC, for so long as a majority of the outstanding Common Stock of the Company is owned by the Initial
Stockholder, its Permitted Transferees and any Fortress Affiliate Stockholder, and thereafter (ii) by the Stockholder participating in such Demand Registration that holds (together with its Permitted Transferees) a number of Registrable
Securities included in such Demand Registration constituting a plurality of all Registrable Securities included in such Demand Registration. 

Section 4.2 Piggyback Registrations. 

(a) Subject to the terms and conditions hereof, whenever the Company proposes to register any of its equity securities under the Securities
Act (other than a registration by the Company (x) on a registration statement on Form S-4 or (y) on a registration statement on Form S-8 (or, in any of the cases of (x) or (y), on any successor forms thereto)) (each, a
“Piggyback Registration”), whether for its own account or for the account of others, the Company shall give the Stockholders (excluding Fortress Affiliate Stockholders which have not signed a joinder as contemplated by Section 2.1)
prompt written notice thereof (but not less than five days prior to the filing by the Company with the Commission of any registration statement with respect thereto). Such notice (a “Piggyback Notice”) shall specify, at a minimum,
the number of equity securities proposed to be registered, the proposed date of filing of such registration statement with the Commission, the proposed means of distribution and the proposed managing underwriter or underwriters (if any and if
known). Upon the written request of any Person that on the date of such Piggyback Notice is a Stockholder, given within five days after such Piggyback Notice is received by such Person (any such Persons, a “Piggyback Seller”) (which
written request shall specify the number of Registrable Securities then presently intended to be disposed of by such Piggyback Seller), the Company, subject to the terms and conditions of this Agreement, shall use its commercially reasonable efforts
to cause all such Registrable Securities held by Piggyback Sellers with respect to which the Company has received such written requests for inclusion to be included in such Piggyback Registration on the same terms and conditions as the
Company’s equity securities being sold in such Piggyback Registration. 
 (b) If, in connection with a Piggyback Registration, any
managing underwriter (or, if such Piggyback Registration is not an Underwritten Offering, a nationally recognized investment bank engaged in connection with such Demand Registration) advises the Company in writing that, in its opinion, the inclusion
of all the equity securities sought to be included in such Piggyback Registration by (i) the Company, (ii) others who have sought to have equity securities of the Company registered in such Piggyback Registration pursuant to rights to
demand (other than pursuant to so-called “piggyback” or other incidental or participation registration rights) such registration (such Persons being “Other Demanding Sellers”), (iii) the Piggyback Sellers and
(iv) any other proposed sellers of equity securities of the Company (such Persons being “Other Proposed Sellers”), as the case may be, would adversely affect the marketability of the equity securities sought to be sold pursuant
thereto, then the Company shall include in the registration statement applicable to such Piggyback Registration only such equity securities as the Company is so advised by such underwriter or investment bank can be sold without such an effect, as
follows and in the following order of priority: 
 (i) if the Piggyback Registration relates to an offering for the
Company’s own account, then (A) first, such number of equity securities to be sold by the Company as the Company, in its reasonable judgment and acting in good faith and in accordance with sound financial practice, shall have determined,

  
 11 

 
(B) second, Registrable Securities of Piggyback Sellers and securities sought to be registered by Other Demanding Sellers (if any), pro rata on the basis of the number of shares of Common Stock
held by such Piggyback Sellers and Other Demanding Sellers and (C) third, other equity securities held by any Other Proposed Sellers; or 

(ii) if the Piggyback Registration relates to an offering other than for the Company’s own account, then (A) first,
such number of equity securities sought to be registered by each Other Demanding Seller and the Piggyback Sellers (if any), pro rata in proportion to the number of shares of Common Stock held by all such Other Demanding Sellers and Piggyback Sellers
and (B) second, other equity securities held by any Other Proposed Sellers or to be sold by the Company as determined by the Company and with such priorities among them as may from time to time be determined or agreed to by the Company. 

(c) In connection with any Underwritten Offering under this Section 4.2 for the Company’s account, the Company shall not be
required to include a holder’s Registrable Securities in the Underwritten Offering unless such holder accepts the terms of the underwriting as agreed upon between the Company and the underwriters selected by the Company; provided, that any
applicable underwriting agreement includes only customary terms and conditions. 
 (d) If, at any time after giving written notice of its
intention to register any of its equity securities as set forth in this Section 4.2 and prior to the time the registration statement filed in connection with such Piggyback Registration is declared effective, the Company shall determine for any
reason not to register such equity securities, the Company may, at its election, give written notice of such determination to each Stockholder and thereupon shall be relieved of its obligation to register any Registrable Securities in connection
with such particular withdrawn or abandoned Piggyback Registration (but not from its obligation to pay the Registration Expenses in connection therewith as provided herein); provided, that Stockholders may continue the registration as a Demand
Registration pursuant to the terms of Section 4.1. 
 Section 4.3 Shelf Registration. 

(a) Subject to Section 4.3(e), and further subject to the availability of a Registration Statement on Form S-3 or a successor form,
which may be an automatically effective registration statement at any time the Company is eligible (“Form S-3”) to the Company, the Initial Stockholder or any of its Permitted Transferees (in each case to the extent a
Stockholder hereunder) may by written notice delivered (which notice can be delivered at any time after the eleven month anniversary of the date hereof) to the Company (the “Shelf Notice”) require the Company to (i) file as
promptly as practicable (but no later than 30 days after the date the Shelf Notice is delivered), and to use commercially reasonable efforts to cause to be declared effective by the Commission at the earliest possible date permitted under the
rules and regulations of the Commission (but no later than 60 days after such filing date), a Form S-3, or (ii) use an existing Form S-3 filed with the Commission, in each case providing for an offering to be made on a continuous basis
pursuant to Rule 415 under the Securities Act relating to the offer and sale, from time to time, of the Registrable Securities owned by the Initial Stockholder or the Fortress 

  
 12 

 
Affiliate Stockholders (or any of their Permitted Transferees), as the case may be, and any other Persons that at the time of the Shelf Notice meet the definition of a Stockholder who elect to
participate therein as provided in Section 4.3(b) (a “Shelf Registration Statement”). 
 (b) The Initial Stockholder
and its Permitted Transferees shall be entitled to require the Company to file an unlimited number of Shelf Registration Statements until such time as the Stockholders, together, Beneficially Own less than a Registrable Amount. 

(c) Within five business days after receipt of a Shelf Notice pursuant to Section 4.3(a), the Company will deliver written notice
thereof to each Stockholder (excluding Fortress Affiliate Stockholders which have not signed a joinder as contemplated by Section 2.1). Each Stockholder may elect to participate in the Shelf Registration Statement by delivering to the Company a
written request to so participate. 
 (d) Subject to Section 4.3(e), the Company will use commercially reasonable efforts to keep the
Shelf Registration Statement continuously effective until the date on which all Registrable Securities covered by the Shelf Registration Statement have been sold thereunder in accordance with the plan and method of distribution disclosed in the
prospectus included in the Shelf Registration Statement, or otherwise (the “Shelf Registration Effectiveness Period”). 

(e) Notwithstanding anything to the contrary contained in this Agreement, the Company shall be entitled, from time to time, by providing
notice to the Stockholders who elected to participate in the Shelf Registration Statement, to require such Stockholders to suspend the use of the prospectus for sales of Registrable Securities under the Shelf Registration Statement for a reasonable
period of time not to exceed 60 days in succession or 90 days in the aggregate in any 12 month period (a “Suspension Period”) if the Board determines in good faith and in its reasonable judgment that it is required to
disclose in the Shelf Registration Statement material, non-public information that the Company has a bona fide business purpose for preserving as confidential. Immediately upon receipt of such notice, the Stockholders covered by the Shelf
Registration Statement shall suspend the use of the prospectus until the requisite changes to the prospectus have been made as required below. Any Suspension Period shall terminate at such time as the public disclosure of such information is made.
After the expiration of any Suspension Period and without any further request from a Stockholder, the Company shall as promptly as practicable prepare a post-effective amendment or supplement to the Shelf Registration Statement or the prospectus, or
any document incorporated therein by reference, or file any other required document so that, as thereafter delivered to purchasers of the Registrable Securities included therein, the prospectus will not include an untrue statement of a material fact
or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(f) At any time, and from time-to-time, during the Shelf Registration Effectiveness Period (except during a Suspension Period), each of the
Initial Stockholder, the Fortress Affiliate Stockholders or any of their Permitted Transferees (in each case to the extent a Stockholder hereunder) may notify the Company of their intent to sell Registrable Securities covered by the Shelf
Registration Statement (in whole or in part) in an Underwritten Offering (a “Shelf Underwritten Offering”); provided that the Company shall not be obligated to participate in more than four underwritten offerings during any
twelve-month period. Such notice shall specify (x) the aggregate number of Registrable Securities requested to be registered in such Shelf 

  
 13 

 
Underwritten Offering and (y) the identity of the Stockholder(s) requesting such Shelf Underwritten Offering. Upon receipt by the Company of such notice, the Company shall promptly comply
with the applicable provisions of this Agreement, including those provisions of Section 4.5 relating the Company’s obligation to make filings with the Commission, assist in the preparation and filing with the Commission of prospectus
supplements and amendments to the Shelf Registration Statement, participate in “road shows,” agree to customary “lock-up” agreements with respect to the Company’s securities and obtain “comfort” letters, and the
Company shall take such other actions as necessary or appropriate to permit the consummation of such Shelf Underwritten Offering as promptly as practicable. Each Shelf Underwritten Offering shall be for the sale of a number of Registrable Securities
equal to or greater than the Registrable Amount. In any Shelf Underwritten Offering, the Company shall select the investment bank(s) and managers that will serve as lead or co-managing underwriters with respect to the offering of such Registrable
Securities, which shall be reasonably acceptable to the Stockholders participating in such Shelf Underwritten Offering that hold a majority of the Registrable Securities included in such Shelf Underwritten Offering. 

Section 4.4 Withdrawal Rights. Any Stockholder having notified or directed the Company to include any or all of its Registrable
Securities in a registration statement under the Securities Act shall have the right to withdraw any such notice or direction with respect to any or all of the Registrable Securities designated by it for registration by giving written notice to such
effect to the Company prior to the effective date of such registration statement. In the event of any such withdrawal, the Company shall not include such Registrable Securities in the applicable registration and such Registrable Securities shall
continue to be Registrable Securities for all purposes of this Agreement. No such withdrawal shall affect the obligations of the Company with respect to the Registrable Securities not so withdrawn; provided, however, that in the case of a Demand
Registration, if such withdrawal shall reduce the number of Registrable Securities sought to be included in such registration below the Registrable Amount, then the Company shall as promptly as practicable give each holder of Registrable Securities
sought to be registered notice to such effect and, within ten days following the mailing of such notice, such holder(s) of Registrable Securities still seeking registration shall, by written notice to the Company, elect to register additional
Registrable Securities, when taken together with elections to register Registrable Securities by its Permitted Transferees, to satisfy the Registrable Amount or elect that such registration statement not be filed or, if theretofore filed, be
withdrawn. During such ten day period, the Company shall not file such registration statement if not theretofore filed or, if such registration statement has been theretofore filed, the Company shall not seek, and shall use commercially reasonable
efforts to prevent, the effectiveness thereof. 
 Section 4.5 Registration Procedures. 

(a) If and whenever the Company is required to use commercially reasonable efforts to effect the registration of any Registrable Securities
under the Securities Act as provided in Sections 4.1, 4.2 and 4.3, the Company shall as promptly as practicable (in each case, to the extent applicable): 

(i) prepare and file with the Commission a registration statement to effect such registration, cause such registration
statement to become effective at the earliest possible date permitted under the rules and regulations of the Commission, and thereafter use commercially reasonable efforts to cause such 

  
 14 

 
registration statement to remain effective pursuant to the terms of this Agreement; provided, however, that the Company may discontinue any registration of its securities which are not
Registrable Securities at any time prior to the effective date of the registration statement relating thereto; provided, further that before filing such registration statement or any amendments thereto, the Company will furnish to the counsel
selected by the holders of Registrable Securities which are to be included in such registration (“Selling Holders”) copies of all such documents proposed to be filed, which documents will be subject to the review of and comment by
such counsel (it being understood that counsel to the Selling Holders will conduct its review and provide any comments promptly); 

(ii) prepare and file with the Commission such amendments (including post-effective amendments) and supplements to such
registration statement and the prospectus used in connection therewith and any Exchange Act reports incorporated by reference therein as may be necessary to keep such registration statement effective and to comply with the provisions of the
Securities Act with respect to the disposition of all securities covered by such registration statement until the earlier of such time as all of such securities have been disposed of in accordance with the intended methods of disposition by the
Selling Holder(s) set forth in such registration statement or (i) in the case of a Demand Registration pursuant to Section 4.1, the expiration of 60 days after such registration statement becomes effective or (ii) in the case of a
Piggyback Registration pursuant to Section 4.2, the expiration of 60 days after such registration statement becomes effective or (iii) in the case of a Shelf Registration pursuant to Section 4.3, the Shelf Registration Effectiveness
Period; 
 (iii) furnish to each Selling Holder and each underwriter, if any, of the securities being sold by such Selling
Holder such number of conformed copies of such registration statement and of each amendment and supplement thereto (in each case including all exhibits), such number of copies of the prospectus contained in such registration statement (including
each preliminary prospectus and any summary prospectus) and any other prospectus filed under Rule 424 under the Securities Act, in conformity with the requirements of the Securities Act, and any Issuer Free Writing Prospectus and such other
documents as such Selling Holder and underwriter, if any, may reasonably request in order to facilitate the public sale or other disposition of the Registrable Securities owned by such Selling Holder; 

(iv) use commercially reasonable efforts to register or qualify such Registrable Securities covered by such registration
statement under such other securities laws or blue sky laws of such jurisdictions as any Selling Holder and any underwriter of the securities being sold by such Selling Holder shall reasonably request, and take any other action which may be
reasonably necessary or advisable to enable such Selling Holder and underwriter to consummate the disposition in such jurisdictions of the Registrable Securities owned by such Selling Holder, except that the Company shall not for any such purpose be
required to qualify generally to do business as a foreign corporation in 

  
 15 

 
any jurisdiction wherein it would not but for the requirements of this clause (iv) be obligated to be so qualified, to subject itself to taxation in any such jurisdiction or to file a
general consent to service of process in any such jurisdiction; 
 (v) use best efforts to cause such Registrable Securities
to be listed on each securities exchange on which similar securities issued by the Company are then listed and, if no such securities are so listed, use commercially reasonable efforts to cause such Registrable Securities to be listed on the NYSE or
the Nasdaq Stock Market; 
 (vi) use commercially reasonable efforts to cause such Registrable Securities covered by such
registration statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the Selling Holder(s) thereof to consummate the disposition of such Registrable Securities; 

(vii) in connection with an Underwritten Offering, obtain for each Selling Holder and underwriter: 

(1) an opinion of counsel for the Company, covering the matters customarily covered in opinions requested in underwritten
offerings and such other matters as may be reasonably requested by such Selling Holder and underwriters, and 
 (2) a
“comfort” letter (or, in the case of any such Person which does not satisfy the conditions for receipt of a “comfort” letter specified in AU Section 634 of the AICPA Professional Standards, an “agreed upon
procedures” letter) signed by the independent registered public accountants who have certified the Company’s financial statements included in such registration statement (and, if necessary, any other independent registered public
accountant of any Subsidiary of the Company or any business acquired by the Company from which financial statements and financial data are, or are required to be, included in the registration statement); ; 

(viii) promptly make available for inspection by any Selling Holder, any underwriter participating in any disposition pursuant
to any registration statement, and any attorney, accountant or other agent or representative retained by any such Selling Holder or underwriter (collectively, the “Inspectors”), all financial and other records, pertinent corporate
documents and properties of the Company (collectively, the “Records”), as shall be reasonably necessary to enable such Selling Holder or underwriter to exercise their due diligence responsibility, and cause the Company’s
officers, directors and employees to supply all information requested by any such Inspector in connection with such registration statement promptly; provided, however, that, unless the disclosure of such Records is necessary to avoid or correct a
misstatement or omission in the registration statement or the release of such Records is ordered pursuant to a subpoena or other order from a court of competent jurisdiction, the Company shall not be required to provide any

  
 16 

 
information under this subparagraph (viii) if (i) the Company believes, after consultation with counsel for the Company, that to do so would cause the Company to forfeit an
attorney-client privilege that was applicable to such information or (ii) if either (A) the Company has requested and been granted from the Commission confidential treatment of such information contained in any filing with the Commission
or documents provided supplementally or otherwise or (B) the Company reasonably determines in good faith that such Records are confidential and so notifies the Inspectors in writing unless prior to furnishing any such information with respect
to (i) or (ii) such holder of Registrable Securities requesting such information agrees, and causes each of its Inspectors, to enter into a confidentiality agreement on terms reasonably acceptable to the Company; and provided, further,
that each Holder of Registrable Securities agrees that it will, upon learning that disclosure of such Records is sought in a court of competent jurisdiction, give notice to the Company and allow the Company, at its expense, to undertake appropriate
action and to prevent disclosure of the Records deemed confidential; 
 (ix) promptly notify in writing each Selling Holder
and the underwriters, if any, of the following events: 
 (1) the filing of the registration statement, the prospectus or
any prospectus supplement related thereto, any Issuer Free Writing Prospectus or post-effective amendment to the registration statement, and, with respect to the registration statement or any post-effective amendment thereto, when the same has
become effective; 
 (2) any request by the Commission for amendments or supplements to the registration statement or the
prospectus or for additional information; 
 (3) the issuance by the Commission of any stop order suspending the
effectiveness of the registration statement or the initiation of any proceedings by any Person for that purpose; 
 (4) when
any Issuer Free Writing Prospectus includes information that may conflict with the information contained in the registration statement; and 

(5) the receipt by the Company of any notification with respect to the suspension of the qualification of any Registrable
Securities for sale under the securities or blue sky laws of any jurisdiction or the initiation or threat of any proceeding for such purpose; 

(x) notify each Selling Holder, at any time when a prospectus relating thereto is required to be delivered under the
Securities Act, upon discovery that, or upon the happening of any event as a result of which, the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state any material
fact required to 

  
 17 

 
be stated therein or necessary to make the statements therein not misleading, and, at the request of any Selling Holder, promptly prepare and furnish to such Selling Holder a reasonable number of
copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not include an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading; 
 (xi) use
every reasonable best effort to obtain the withdrawal of any order suspending the effectiveness of such registration statement; 

(xii) otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission, and
make available to Selling Holders, as promptly as practicable, an earnings statement covering the period of at least 12 months, but not more than 18 months, beginning with the first day of the Company’s first full quarter after the effective
date of such registration statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder; 

(xiii) use its reasonable best efforts to assist Stockholders who made a request to the Company to provide for a third party
“market maker” for the Common Stock; provided, however, that the Company shall not be required to serve as such “market maker”; 

(xiv) cooperate with any Selling Holder and any underwriter and the managing underwriter to facilitate the timely preparation
and delivery of certificates (which shall not bear any restrictive legends unless required under applicable law), if necessary or appropriate, representing securities sold under any registration statement, and enable such securities to be in such
denominations and registered in such names as the managing underwriter or such Selling Holder may request and keep available and make available to the Company’s transfer agent prior to the effectiveness of such registration statement a supply
of such certificates as necessary or appropriate; 
 (xv) have appropriate officers of the Company prepare and make
presentations at any “road shows” and before analysts and rating agencies, as the case may be, take other actions to obtain ratings for any Registrable Securities (if they are eligible to be rated) and otherwise use its reasonable best
efforts to cooperate as reasonably requested by the Selling Holders and the underwriters in the offering, marketing or selling of the Registrable Securities; 

(xvi) have appropriate officers of the Company, and cause representatives of the Company’s independent registered public
accountants, to participate in any due diligence discussions reasonably requested by any Selling Holder or any underwriter; 

  
 18 

 (xvii) if requested by any underwriter, agree, and cause the Company and any
directors or officers of the Company to agree, to be bound by customary “lock-up” agreements restricting the ability to dispose of Company securities; 

(xviii) if requested by any Selling Holders or any underwriter, promptly incorporate in the registration statement or any
prospectus, pursuant to a supplement or post-effective amendment if necessary, such information as such Selling Holders may reasonably request to have included therein, including information relating to the “Plan of Distribution” of the
Registrable Securities; 
 (xix) cooperate and assist in any filings required to be made with the FINRA and in the
performance of any due diligence investigation by any underwriter that is required to be undertaken in accordance with the rules and regulations of the FINRA; 

(xx) otherwise use reasonable best efforts to cooperate as reasonably requested by the Selling Holders and the underwriters in
the offering, marketing or selling of the Registrable Securities; 
 (xxi) otherwise use commercially reasonable efforts to
comply with all applicable rules and regulations of the Commission and all reporting requirements under the rules and regulations of the Exchange Act; and 

(xxii) use reasonable best efforts to take any action requested by the Selling Holders, including any action described in
clauses (i) through (xxi) above to prepare for and facilitate any “over-night deal” or other proposed sale of Registrable Securities over a limited timeframe. 

The Company may require each Selling Holder and each underwriter, if any, to furnish the Company in writing such information regarding each Selling Holder or
underwriter and the distribution of such Registrable Securities as the Company may from time to time reasonably request to complete or amend the information required by such registration statement. 

(b) Without limiting any of the foregoing, in the event that the offering of Registrable Securities is to be made by or through an
underwriter, the Company shall enter into an underwriting agreement with a managing underwriter or underwriters containing representations, warranties, indemnities and agreements customarily included (but not inconsistent with the covenants and
agreements of the Company contained herein) by an issuer of common stock in underwriting agreements with respect to offerings of common stock for the account of, or on behalf of, such issuers. In connection with any offering of Registrable
Securities registered pursuant to this Agreement, the Company shall furnish to the underwriter, if any (or, if no underwriter, the Selling Holder), unlegended certificates representing ownership of the Registrable Securities being sold (unless, in
the Company’s sole discretion, such Registrable Securities are to be issued in uncertificated form pursuant to the customary arrangements for issuing shares in such form), in such denominations as requested and instruct any transfer agent and
registrar of the Registrable Securities to release any stop transfer order with respect thereto. 

  
 19 

 (c) Each Selling Holder agrees that upon receipt of any notice from the Company of the happening
of any event of the kind described in Section 4.5(a)(ix), such Selling Holder shall forthwith discontinue such Selling Holder’s disposition of Registrable Securities pursuant to the applicable registration statement and prospectus relating
thereto until such Selling Holder’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 4.5(a)(ix) and, if so directed by the Company, deliver to the Company, at the Company’s expense, all copies,
other than permanent file copies, then in such Selling Holder’s possession of the prospectus current at the time of receipt of such notice relating to such Registrable Securities. In the event the Company shall give such notice, any applicable
60 day period during which such registration statement must remain effective pursuant to this Agreement shall be extended by the number of days during the period from the date of giving of a notice regarding the happening of an event of the kind
described in Section 4.5(a)(ix) to the date when all such Selling Holders shall receive such a supplemented or amended prospectus and such prospectus shall have been filed with the Commission. 

Section 4.6 Registration Expenses. 

(a) All expenses incident to the Company’s performance of, or compliance with, its obligations under this Agreement including
(i)(A) all registration and filing fees, all fees and expenses of compliance with securities and “blue sky” laws, (B) all fees and expenses associated with filings required to be made with FINRA (including, if applicable, the
fees and expenses of any “qualified independent underwriter” as such term is defined in NASD Rule 2720 or the equivalent rule incorporated into the FINRA rulebook), (C) all fees and expenses of compliance with securities and
“blue sky” laws, (D) all printing (including expenses of printing certificates, if any, for the Registrable Securities in a form eligible for deposit with the Depository Trust Company and of printing prospectuses if the printing of
prospectuses and Issuer Free Writing Prospectuses is requested by a holder of Registrable Securities) and copying expenses, (E) all messenger and delivery expenses, (F) all fees and expenses of the Company’s independent certified
public accountants and counsel (including with respect to “comfort” letters, “agreed-upon procedures” letter and opinions), (G) fees and expenses of one counsel to the Stockholders selling in such registration (which firm
shall be selected by the Stockholders selling in such registration that hold a majority of the Registrable Securities included in such registration), (H) except as provided in clause (ii) below, the fees and expenses (including
underwriting discounts and commissions and transfer taxes) of every nationally recognized investment bank engaged in connection with a Demand Registration or a Piggyback Registration that is not an Underwritten Offering, (collectively, the
“Registration Expenses”) and (ii) any expenses described in clauses (i)(A) through (H) above incurred in connection with the marketing and sale of Registrable Securities (“Offering Expenses”) shall be
borne by the Company, regardless of whether a registration is effected, marketing is commenced or sale is made. The Company will pay its internal expenses (including all salaries and expenses of its officers and employees performing legal or
accounting duties, the expense of any annual audit and the expense of any liability insurance) and the expenses and fees for listing the securities to be registered on each securities exchange and included in each established over-the-counter market
on which similar securities issued by the Company are then listed or traded. 
 (b) Each Selling Holder shall pay its portion of all
underwriting discounts and commissions and transfer taxes, if any, relating to the sale of such Selling Holder’s Registrable Securities pursuant to any registration. 

  
 20 

 ARTICLE V 

INDEMNIFICATION 

Section 5.1 General Indemnification. The Company agrees to indemnify and hold harmless the Initial Stockholder and each of the
officers, directors, employees, members, managers, partners and agents or Affiliates of the Initial Stockholder against any and all losses, claims, damages, liabilities and expenses (including reasonable expenses of investigation and reasonable
attorneys’ fees and expenses) (collectively, the “Losses”), in each case, based on, arising out of, resulting from or in connection with any claim, action, cause of action, suit, proceeding or investigation, whether civil,
criminal, administrative, investigative or other (collectively, “Actions”), based on, arising out of, pertaining to or in connection with (i) the ownership or the operation of the assets or properties, and the operation or
conduct of the business of, including contracts entered into by, the Company, whether before, on or after the date hereof (ii) any other activity that the Company or its Subsidiaries engages in and (iii) any untrue statement or alleged
untrue statement of a material fact contained in any Filing or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, other than misstatements or
omissions made in reliance on information relating to and furnished by the Initial Stockholder in writing expressly for use in the preparation of such Filing. The indemnity agreement contained in this Section 5.1 shall be applicable whether or
not any Action or the facts or transactions giving rise to such Action arose prior to, on or subsequent to the date of this Agreement. 

Section 5.2 Registration Statement Indemnification. 

(a) The Company agrees to indemnify and hold harmless, to the fullest extent permitted by law, each Selling Holder, its officers, directors,
employees, managers, members, partners and Affiliates, such Selling Holder or such other indemnified Person from and against all Losses caused by, resulting from or relating to any untrue statement (or alleged untrue statement) of a material fact
contained in any registration statement, any Issuer Free Writing Prospectus, any prospectus or preliminary prospectus or any amendment thereof or supplement thereto or any omission (or alleged omission) of a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, except insofar as the same are caused by any information furnished in writing to the Company by such Selling Holder
expressly for use therein. In connection with an Underwritten Offering and without limiting any of the Company’s other obligations under this Agreement, the Company shall also indemnify such underwriters, their officers, directors, employees
and agents and each Person who controls (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act) such underwriters or such other indemnified Person to the same extent as provided above with respect to the
indemnification (and exceptions thereto) of the holders of Registrable Securities being sold. Reimbursements payable pursuant to the indemnification contemplated by this Section 5.2(a) will be made by periodic payments during the course of any
investigation or defense, as and when bills are received or expenses incurred. 

  
 21 

 (b) In connection with any registration statement in which a holder of Registrable Securities is
participating, each such Selling Holder will furnish to the Company in writing information regarding such Selling Holder’s ownership of Registrable Securities and its intended method of distribution thereof and, to the extent permitted by law,
shall, severally and not jointly, indemnify the Company, its directors, officers, employees and agents and each Person who controls (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act) the Company or
such other indemnified Person against all Losses caused by any untrue statement of material fact contained in the registration statement, any Issuer Free Writing Prospectus, any prospectus or preliminary prospectus or any amendment thereof or
supplement thereto or any omission of a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, but only to the extent that such untrue
statement or omission is caused by and contained in such information so furnished in writing by such Selling Holder expressly for use therein; provided, however, that each Selling Holder’s obligation to indemnify the Company hereunder shall, to
the extent more than one Selling Holder is subject to the same indemnification obligation, be apportioned between each Selling Holder based upon the net amount received by each Selling Holder from the sale of Registrable Securities, as compared to
the total net amount received by all of the Selling Holders of Registrable Securities sold pursuant to such registration statement. Notwithstanding the foregoing, no Selling Holder shall be liable to the Company for amounts in excess of the lesser
of (i) such apportionment and (ii) the net amount received by such holder in the offering giving rise to such liability. 

Section 5.3 Contribution. 

(a) If recovery is not available under the foregoing indemnification provisions for any reason or reasons other than as specified therein,
any Person who would otherwise be entitled to indemnification by the terms thereof shall nevertheless be entitled to contribution with respect to any Losses with respect to which such Person would be entitled to such indemnification but for such
reason or reasons. In determining the amount of contribution to which the respective Persons are entitled, there shall be considered the Persons’ relative knowledge and access to information concerning the matter with respect to which the claim
was asserted, the opportunity to correct and prevent any statement or omission, and other equitable considerations appropriate under the circumstances. It is hereby agreed that it would not necessarily be equitable if the amount of such contribution
were determined by pro rata or per capita allocation. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not found guilty of
such fraudulent misrepresentation. Notwithstanding the foregoing, no Selling Holder or transferee thereof shall be required to make a contribution in excess of the net amount received by such holder from its sale of Registrable Securities in
connection with the offering that gave rise to the contribution obligation. 

  
 22 

 Section 5.4 Procedure. 

(a) Any Person entitled to indemnification hereunder shall give prompt written notice to the indemnifying party of any claim with respect to
which it seeks indemnification; provided, however, the failure to give such notice shall not release the indemnifying party from its obligation, except to the extent that the indemnifying party has been materially prejudiced by such failure to
provide such notice on a timely basis. 
 (b) In any case in which any such action is brought against any indemnified party, and it
notifies an indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein, and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense
thereof, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not (so long as it shall
continue to have the right to defend, contest, litigate and settle the matter in question in accordance with this paragraph) be liable to such indemnified party hereunder for any legal or other expense subsequently incurred by such indemnified party
in connection with the defense thereof other than reasonable costs of investigation, supervision and monitoring (unless (i) such indemnified party reasonably objects to such assumption on the grounds that there may be defenses available to it
which are different from or in addition to the defenses available to such indemnifying party or (ii) the indemnifying party shall have failed within a reasonable period of time to assume such defense and the indemnified party is or is
reasonably likely to be prejudiced by such delay, in either event the indemnified party shall be promptly reimbursed by the indemnifying party for the expenses incurred in connection with retaining separate legal counsel). The indemnifying party
shall lose its right to defend, contest, litigate and settle a matter if it shall fail to diligently contest such matter (except to the extent settled in accordance with the next following sentence). 

Section 5.5 Other Matters. 

(a) An indemnifying party shall not be liable for any settlement of an Action effected without its consent. No indemnifying party shall,
without the prior written consent of the indemnified party, effect any settlement of any pending or threatened Action in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such
indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such Action. 

(b) Any Losses for which an indemnified party is entitled to indemnification or contribution under this Article V shall be paid by the
indemnifying party to the indemnified party as such Losses are incurred. The indemnity and contribution agreements contained in this Article V shall remain operative and in full force and effect, regardless of (i) any investigation made by or
on behalf of any Indemnitee, the Company, its directors or officers, or any person controlling the Company, and (ii) any termination of this Agreement. 

(c) The parties hereto shall, and shall cause their respective Subsidiaries to, cooperate with each other in a reasonable manner with respect
to access to unprivileged information and similar matters in connection with any Action. The provisions of this Article V are for the benefit of, and are intended to create third party beneficiary rights in favor of, each of the indemnified parties
referred to herein. 

  
 23 

 (d) Not less than three days before the expected filing date of each registration statement
pursuant to this Agreement, the Company shall notify each Stockholder who has timely provided the requisite notice hereunder entitling the Stockholder to register Registrable Securities in such registration statement of the information, documents
and instruments from such Stockholder that the Company or any underwriter reasonably requests in connection with such registration statement, including, but not limited to a questionnaire, custody agreement, power of attorney, lock-up letter and
underwriting agreement (the “Requested Information”). If the Company has not received, on or before the day before the expected filing date, the Requested Information from such Stockholder, the Company may file the Registration
Statement without including Registrable Securities of such Stockholder. The failure to so include in any registration statement the Registrable Securities of a Stockholder (with regard to that registration statement) shall not in and of itself
result in any liability on the part of the Company to such Stockholder. 
 ARTICLE VI 

MISCELLANEOUS 

Section 6.1 Headings. The headings in this Agreement are for convenience of reference only and shall not control or effect the
meaning or construction of any provisions hereof. 
 Section 6.2 Entire Agreement. This Agreement constitutes the entire
agreement and understanding of the parties hereto in respect of the subject matter contained herein, and there are no restrictions, promises, representations, warranties, covenants, conditions or undertakings with respect to the subject matter
hereof, other than those expressly set forth or referred to herein. This Agreement supersedes all prior agreements and understandings between the parties hereto with respect to the subject matter hereof. 

Section 6.3 Further Actions; Cooperation. Each of the Stockholders agrees to use its reasonable efforts to take, or cause to be
taken, all actions and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable to give effect to the transactions contemplated by this Agreement. Without limiting the
generality of the foregoing, each of the Stockholders (i) acknowledges that such Stockholder will prepare and file with the Commission filings under the Exchange Act, including under Section 13(d) of the Exchange Act, relating to its
Beneficial Ownership of the Common Stock and (ii) agrees to use its reasonable efforts to assist and cooperate with the other parties in promptly preparing, reviewing and executing any such filings under the Exchange Act, including any
amendments thereto. 

  
 24 

 Section 6.4 Notices. All notices, requests, consents and other communications
hereunder to any party shall be deemed to be sufficient if contained in a written instrument delivered in person or sent by facsimile, nationally recognized overnight courier or first class registered or certified mail, return receipt requested,
postage prepaid, addressed to such party at the address set forth below or such other address as may hereafter be designated on the signature pages of this Agreement or in writing by such party to the other parties: 

If to the Initial Stockholder, to: 

Springleaf Financial Holdings, LLC 

c/o Fortress Investment Group LLC 

1345 Avenue of the Americas, 46th Floor 

New York, NY 10105 
 Fax:
(212) 798-6122 
 Email: rnardone@fortress.com 

Attn: Randal A. Nardone 
 with a
copy (which shall not constitute notice) to: 
 Skadden, Arps, Slate, Meagher & Flom LLP 

4 Times Square 
 New York, NY
10036-6522 
 Fax: (212) 735-2000 

Email: gregory.fernicola@skadden.com 

Attn:  Gregory A.Fernicola, Esq. 

If to the Company, to: 

Springleaf Holdings, Inc. 
 601
N.W. Second Street 
 Evansville, IN 47708 

Email: scott.mckinlay@slfs.com 

Attn: General Counsel 
 If to a
Stockholder that is not the Initial Stockholder, then to the address set forth in the written agreement of such Stockholder provided for in Section 2.1 hereof. 

All such notices, requests, consents and other communications shall be deemed to have been given or made if and when received (including by
overnight courier) by the parties at the above addresses or sent by email, facsimile, with confirmation received, to the email addresses or facsimile numbers specified above (or at such other address or facsimile number for a party as shall be
specified by like notice). Any notice delivered by any party hereto to any other party hereto shall also be delivered to each other party hereto simultaneously with delivery to the first party receiving such notice. 

Section 6.5 Applicable Law. The substantive laws of the State of New York shall govern the interpretation, validity and
performance of the terms of this Agreement, without regard to conflicts of law doctrines. 
 Section 6.6 Severability. The
provisions of this Agreement are independent of and separable from each other. The invalidity, illegality or unenforceability of one or more of the provisions of this Agreement in any jurisdiction shall not affect the validity, legality or
enforceability of the remainder of this Agreement, including any such provisions, in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law. The
parties hereto shall endeavor in good faith 

  
 25 

 
negotiations to replace any invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or
unenforceable provision, as applicable. 
 Section 6.7 Successors and Assigns. Except as otherwise provided herein, all the
terms and provisions of this Agreement shall be binding upon, shall inure to the benefit of and shall be enforceable by the respective successors and permitted assigns of the parties hereto. No Stockholder may assign any of its rights hereunder to
any Person other than a Permitted Transferee. Each Permitted Transferee of any Stockholder shall be subject to all of the terms of this Agreement, and by taking and holding such shares such Person shall be entitled to receive the benefits of and be
conclusively deemed to have agreed to be bound by and to comply with all of the terms and provisions of this Agreement; provided, however, no transfer of rights permitted hereunder shall be binding upon or obligate the Company unless and until
(i) if required under Section 2.1 hereof, the Company shall have received written notice of such transfer and the joinder of the transferee provided for in Section 2.1 hereof, and (ii) such transferee can establish Beneficial
Ownership or ownership of record of a Registrable Amount (whether individually or together with its Affiliates that are Stockholders or transferees of Stockholders and, if applicable, its other Permitted Transferees that are Stockholders or
transferees of Stockholders). The Company may not assign any of its rights or obligations hereunder without the prior written consent of each of the Stockholders, and any assignment attempted or effected without obtaining such required consent shall
be null and void. Notwithstanding the foregoing, no successor or assignee of the Company shall have any rights granted under this Agreement until such Person shall acknowledge its rights and obligations hereunder by a signed written statement of
such Person’s acceptance of such rights and obligations. 
 Section 6.8 Amendments. This Agreement may not be amended,
modified or supplemented unless such amendment, modification or supplement is in writing and signed by each of the Stockholders and the Company. 

Section 6.9 Waiver. The failure of a party hereto at any time or times to require performance of any provision hereof shall in no
manner affect its right at a later time to enforce the same. No waiver by a party of any condition or of any breach of any term, covenant, representation or warranty contained in this Agreement shall be effective unless in a writing signed by the
party against whom the waiver is to be effective, and no waiver in any one or more instances shall be deemed to be a further or continuing waiver of any such condition or breach in other instances or a waiver of any other condition or breach of any
other term, covenant, representation or warranty. 
 Section 6.10 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original but all of which shall constitute one and the same Agreement. 
 Section 6.11
Submission To Jurisdiction. ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT AND ANY ACTION FOR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF MAY BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK LOCATED IN THE BOROUGH OF
MANHATTAN OR OF THE UNITED STATES OF AMERICA FOR THE SOUTHERN DISTRICT OF NEW YORK AND, BY EXECUTION AND DELIVERY OF THIS 

  
 26 

 
AGREEMENT, EACH PARTY HERETO HEREBY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, THE NON-EXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND THE APPELLATE
COURTS THEREOF. EACH PARTY HERETO IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS OUT OF ANY OF THE AFOREMENTIONED COURTS IN ANY SUCH ACTION OR PROCEEDING BY THE MAILING OF COPIES THEREOF BY REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, TO SUCH
PARTY AT THE ADDRESS FOR NOTICES SET FORTH HEREIN. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY OF THE AFORESAID ACTIONS OR PROCEEDINGS ARISING OUT OF OR IN CONNECTION
WITH THIS AGREEMENT BROUGHT IN THE COURTS REFERRED TO ABOVE AND HEREBY FURTHER IRREVOCABLY WAIVES AND AGREES NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT
FORUM. THE PARTIES HERETO WAIVE THEIR RIGHT TO A JURY TRIAL WITH RESPECT TO DISPUTES HEREUNDER. 
 Section 6.12 Injunctive
Relief. Each party hereto acknowledges and agrees that a violation of any of the terms of this Agreement will cause the other parties irreparable injury for which an adequate remedy at law is not available. Therefore, the Stockholders agree that
each party shall be entitled to, an injunction, restraining order, specific performance or other equitable relief from any court of competent jurisdiction, restraining any party from committing any violations of the provisions of this Agreement,
without the need to post a bond or prove the inadequacy of monetary damages. 
 Section 6.13 Recapitalizations, Exchanges, Etc.
Affecting the Shares of Common Stock; New Issuance. The provisions of this Agreement shall apply, to the full extent set forth herein, with respect to Company Securities and to any and all equity or debt securities of the Company or any
successor or assign of the Company (whether by merger, consolidation, sale of assets, or otherwise) which may be issued in respect of, in exchange for, or in substitution of, such Company Securities and shall be appropriately adjusted for any stock
dividends, splits, reverse splits, combinations, reclassifications, recapitalizations, reorganizations and the like occurring after the date hereof. 

Section 6.14 Termination. Upon the mutual consent of all of the parties hereto or, with respect to each Stockholder, at such
earlier time as such Stockholder and its Affiliates and Permitted Transferees ceases to Beneficially Own a Registrable Amount, the terms of this Agreement shall terminate, and be of no further force and effect; provided, however, that the following
shall survive the termination of this Agreement: (i) the provisions of Sections 4.2 (which shall terminate, and be of no further force and effect, with respect to each Stockholder, at such time as such Stockholder and its Affiliates and
Permitted Transferees ceases to Beneficially Own a Registrable Amount), 4.6, Article 5, 6.5, 6.11, this Section 6.14 and Section 6.15; (ii) the rights with respect to the breach of any provision hereof by the Company and
(iii) any registration rights vested or obligations accrued as of the date of termination of this Agreement to the extent, in the case of registration rights so vested, if such Stockholder ceases to meet the definition of a Stockholder under
this Agreement subsequent to the vesting of such registration rights as a result of action taken by the Company. 

  
 27 

 Section 6.15 Third Party Beneficiary. FIG LLC shall be a third party beneficiary to
the agreements made hereunder between the Company and the Initial Stockholder and shall have the right to enforce such agreements directly to the extent it deems such enforcement necessary or advisable to protect its rights hereunder. 

Section 6.16 Rule 144. The Company covenants and agrees that it will file the reports required to be filed by it under the
Securities Act and the Exchange Act and the rules and regulations adopted by the Commission thereunder (or, if it is not required to file such reports, it will, upon the request of any holder of Registrable Securities, make publicly available other
information so long as necessary to permit sales in compliance with Rule 144 under the Securities Act), and it will take such further reasonable action, to the extent required from time to time to enable such holder to sell Registrable Securities
without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 under the Securities Act, as such Rule 144 may be amended from time to time, or any similar rule or regulation hereafter adopted by the
Commission. Upon the reasonable request of any holder of Registrable Securities, the Company will deliver to such holder a written statement as to whether it has complied with such information and filing requirements. 

Section 6.17 Information. The Company covenants and agrees that for so long as the Stockholders, together, have Beneficial
Ownership of at least 1% of the Voting Power of the Company, it will provide or cause to be provided, upon request, to persons affiliated with FIG LLC who are covered by applicable FIG LLC confidentiality policies, all information about the Company
and its operations as the Company would ordinarily provide to a director upon his or her request. 
 [Remainder of page left blank
intentionally] 

  
 28 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed and delivered by their
respective officers thereunto duly as of the date first above written. 
  

			
	SPRINGLEAF HOLDINGS, INC.
		
	By:	 	  

		 	Name:
		 	Title:
	
	SPRINGLEAF FINANCIAL HOLDINGS, LLC
		
	By:	 	  

		 	Name:
		 	Title:

 [SIGNATURE PAGE TO STOCKHOLDERS AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]